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1. INTRODUCTION
Viral genomes are short, leaving viruses with only limited capacity to encode 
the functions required for their multiplication. In order to compensate this, the 
viruses have evolved several sophisticated means of utilising the molecular 
mechanisms of the cell for achieving their own goals. My studies in the lab and 
the resulting publications that form the basis of the current thesis have dealt 
mainly with virus-cell interactions that govern the establishing and maintenance 
of bovine papillomavirus type 1 (BPV1) genomes as episomal plasmids in 
latently infected cells. These studies are described in the results and discussion 
section of the thesis. In the literature overview section, I am trying to present 
some background information necessary for conceiving the specific objectives 
of these studies.
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2. LITERATURE REVIEW
2.1. Papillomaviruses and BPV1 — general introduction
Papillomaviruses (PV) are a family of epitheliotropic viruses with a relatively 
small (~8kb) double-stranded circular DNA genome, which is packed into a 
small (55nm) icosahedral capsid with no surrounding envelope. The members 
of this family are species-specific and widely distributed in nature. Large 
variety of PV types has been identified from different bird and mammalian 
species, including more than 100 (and counting) from humans. The use of new 
sensitive detection methods (PCR) has revealed that PV infection may remain 
asymptomatic with a surprisingly high frequency and can be more common in 
host populations than previously thought (Antonsson et al., 2000; Antonsson 
and Hansson, 2002; Astori et a l, 1998; Boxman etal., 1997). Visible symptoms 
of the PV infection are mostly presented by periodic benign lesions of infected 
skin and mucosa. These lesions, generally referred to as papillomas, are also 
called ‘warts’, if found on the skin, and ‘condylomas’, if associated with 
genitalia. The interest in studies of PVs has been undoubtedly boosted by the 
fact that some of the human papillomavirus types, like HPV16, HPV18 and 
HPV31, have been demonstrated to associate with neoplastic alterations in 
epithelial tissues, most particularly with cervical cancer (zur Hausen, 2002; 
Walboomers etal., 1999).
Several ungulate PVs form a distinct group in this otherwise epithelitropic 
family. Their infection may cause fibropapillomas, which have clear fibroblastic 
component in addition to epithelial one. Most well known representative of this 
group is bovine papillomavirus BPV 1. In addition to less strict tissue tropism, 
these PVs have also somewhat more relaxed species specificity. For example, 
bovine papillomaviruses BPV1 and BPV2 may cause benign sarcoid tumours 
on horses, donkeys and mules (Campo, 2002). BPV1 can also non-productively 
transform rodent fibroblasts (Breitburd, 1987). The development of relatively 
simple and well-defined in vitro transformation assay of mouse cell-lines has 
been one of the main historic reasons why this bovine virus has emerged as one 
of the prototypes for the research of PV biology.
2.2. Papillomavirus life cycle
The ВPV1-transformed mouse fibroblast cell lines have appeared to be a useful 
tool for studying the early steps in PV life cycle. The full life cycle of PVs 
cannot be followed in this model system, as its completion is tightly linked to 
the epithelial differentiation of host cells. The detailed studies on the later, 
productive stages of the infection were enabled only after the emergence of
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more suitable laboratory model systems. These are based on HPV-carrying 
human keratinocyte cells, which are induced to differentiate either in the 
organotypic raft cultures or by suspension in methylcellulose (Dollard et al., 
1992; Flores and Lambert, 1997; Frattini et al., 1996; Frattini et al., 1997; 
McCance et al., 1988; Meyers et al., 1992; Meyers et al., 1997).
PV particles are capable of recognising and binding to wide variety of cell 
types from several species (Muller et al., 1995; Roden et al., 1994; Volpers et 
al., 1995). Thus, the narrow species specificity and tissue tropism of PVs are 
not determined by host cell recognition, but rather by post-entry steps of the 
viral life cycle. Successful establishing of PV genomic DNA takes place in 
proliferating undifferentiated basal epithelial cells. Viral entry into these cells 
initiates the expression of genes encoding for early viral proteins (including 
viral replication factors) and initial amplification of viral genome takes place. It 
is followed by eventual nuclear establishing of the viral genome as extra- 
chromosomal circular plasmid at stable copy number and viral latency. This 
process is likely to involve the switchover to more controlled genome 
replication mechanism and active partitioning of viral genomes in dividing 
cells. The proliferation of host cells leads to detachment of some of the daughter 
cells from the epithelial basement membrane. These are pushed further upwards 
by growing basal layer, start to stratify and differentiate. Terminal diffe­
rentiation triggers the initiation of final, productive stage of PV life cycle inside 
the host cell. It is characterized by the vegetative amplification of viral geno­
mes, the expression of capsid proteins, and subsequent formation of new viral 
particles. It should be noted, however, that even though the general build-up of 
the life cycle is believed to be the same in the case of all PVs (Howley, 2001), 
some differences are likely to exist in details. For example, the exact timing of 
specific life cycle related events relative to the host cell differentiation status 
has been shown to vary in the case of different PVs (Peh et al., 2002).
2.3. Papillomavirus genome structure and genes
2.3.1. General features
PVs are well defined not only by their similar life cycle. The comparison of 
sequencing data from different PV types has revealed a remarkable conservation 
of the genomic organisation inside the family.
Typical PV genome consists of separate coding and non-coding regions. Up 
to 8 ORFs (E1-E8) can be found in the early transcribed part and two (LI, L2) 
in the late part of the coding region. The early ORFs correspond to non- 
structural and late ORFs to structural proteins, and all the genes are transcribed 
from the same strand of viral DNA. The extent of similarity on the primary
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sequence level in certain parts of coding region has been chosen as a definition 
for new PV types. If it is less than 90% in the combined sequences of E6, E7 
and LI genes, the virus isolate is postulated to represent a new type (de Villiers, 
1994). The non-coding region of PV genome is usually around lkb long and 
consists of sequences vital for the regulation and control of the viral life cycle. 
It is named accordingly as upstream regulatory region (URR) or long control 
region (LCR) and contains the viral origin of replication, transcription enhancer 
elements, and binding sites for various cellular transcription factors as well as 
for viral multifunctional protein E2.
The transcription of PV genome is a complex process. It involves the use of 
different promoters as well as polyadenylation sites and extensive splicing. The 
exact use of these mechanisms in the course of transcription program as well as 
resulting transcripts vary to some extent in the case of different PV types, but 
the overall regulation of this process is always tightly linked to the 
differentiation of host cell. mRNA-s are translated into proteins that have 
considerable homology, both on the primary sequence level as well as on the 
functional level, in different members of the PV family. I will discuss the main 
features of some PV proteins relevant to the specific topic of the current thesis 
in the following sections of this chapter. In the present and the following 
chapters, I am concentrating on the bovine papillomavirus BPV1 as the main 
object of my studies. Even though much of the information is true also in the 
case of other PVs, some features specific to certain types are emphasised where 
appropriate.
2.3.2. E2 as a master regulator
of the papillomavirus life cycle
The protein corresponding to BPV1 E2 ORF was first characterized as 
transcription activator (Spalholz et a l, 1985). Subsequent studies have revealed 
that E2 of BPV 1 as well as other PVs is a multifunctional protein. In addition to 
the regulation of viral transcription, it participates also in several other 
important processes of the PV life cycle, like replication and stable extra- 
chromosomal maintenance (McBride and Myers, 1997; Ustav and Ustav, 1998).
The PV E2 proteins can be expressed in several alternative versions. Besides 
full-length 48kD protein, also two shorter forms — E8/E2 and E2C — are 
translated from alternative BPV1 mRNAs. They are also referred to as E2 rep­
ressor forms, owing to their ability to inhibit the transcription activation (as well 
as other activities) by the full-length E2 transactivator (E2TA). The inhibition 
can be achieved through competing for E2 cognate binding sites and through 
heterodimer formation (Lambert et al., 1989; Lambert et a l, 1987). Both 
repressor forms have intact C-terminal DNA binding (DBD) and dimerisation 
domain, but their N-terminal domain is truncated (Giri and Yaniv, 1988; 
Haugen et a l, 1988; Hirochika et a l, 1987; Hubbert et a l, 1988; McBride et
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al., 1989; McBride et al., 1988). In addition, E8/E2 protein carries also a short 
peptide encoded by E8 ORF in its N-terminus. All three E2 polypeptides 
contain ‘hinge’ region, which links N- and С-terminal domains in the full- 
length protein and is the least conserved part on the primary sequence level of 
this otherwise relatively well conserved protein. Through DBD (which has to be 
in dimerised form), E2 binds to specific consensus sequence ACC(N6)GGT in 
DNA (Androphy et al., 1987; Li et al., 1989). BPV1 genome contains 17 such 
binding sites (BS) with varying exact sequence as well as E2 binding affinity; 
12 of these are localised in URR region (Li et al., 1989).
The binding of E2 to these sites is important for the regulation of viral life 
cycle in several aspects. To begin with, it can activate the transcription from 
viral promoters (Haugen et al., 1987; Hermonat et al., 1988; Spalholz et al., 
1987; Szymanski and Stenlund, 1991). This activity is required for the trans­
formation of cells by BPV1 (Brokaw et al., 1996; DiMaio, 1986; DiMaio and 
Settleman, 1988; Rabson et al., 1986; Sarver et al., 1984), but, interestingly, is 
not essential for carrying out the early and late stages in the life cycle program 
of HPV31 and possibly other oncogenic HPVs (Stubenrauch et al., 1998). 
E2TA proteins of BPV1 and other PVs can bind numerous components of 
cellular transcription machinery, thus acting as recruitment factors contributing 
towards regulating the transcription from promoters adjacent to the E2 binding 
sites. These factors include the components of general transcription machinery, 
such as TATA-binding protein (TBP), TBP-associated factors (TAFs) in TFIID 
complex, TFIIB, and RNA polymerase П (Rank and Lambert, 1995; Steger et 
al., 1995; Wu and Chiang, 2001); as well as several possible co-regulators for 
transcription, such as Spl, Gps2/AMF-1, and TopBPl (Boner et al., 2002; 
Breiding et al., 1997; Li et al., 1991). E2 can also recruit the co-factors that 
possess histone acetyltransferase activity and are thus capable of remodelling 
chromatin structure in the promoter region (Lefebvre et al., 1997). Examples 
include p300 and CREB-binding protein (СВР) as well as p300/CBP-associated 
factor (p/CAF) (Lee et al., 2002; Lee et al., 2000; Peng et al., 2000). 
Efficient transcription activation by E2 requires at least two copies of binding 
sequence (Harrison et al., 1987; Haugen et al., 1987; Hawley-Nelson et al., 
1988; Spalholz et al., 1985). The binding to two neighbouring sites is a 
cooperative process and the determinants for cooperative binding are located in 
the N-terminal domain (Monini etal., 1991; Thierry et al., 1990).
Full-length E2 proteins of different PVs can also repress the transcription 
from certain viral promoters, both passively, through sterically interfering with 
binding of the components of transcription initiation complex to the promoter 
(Demeret et al., 1994; Dong et al., 1994; Dostatni et al., 1991; Tan et al., 1994; 
Vande Pol and Howley, 1990) as well as through actively interfering with some 
steps after TBP or TFIID binding (Hou et al., 2000). However, the significance 
of this activity in viral life cycle remains to be determined. At least in the case 
of HPV16, the repression of specific early promoter has been shown to occur in 
viral genomes that are integrated into host genome but not on normal episomal
4 13
copies, possibly as a result of alternative chromatin structure in the promoter 
region (Bechtold et a l, 2003). It is possible that both transactivation and rep­
ressor functions of E2 may be of secondary importance for efficient main­
tenance of certain PV types in host cells.
Perhaps one of the most important functions of the E2 protein in PV life 
cycle is its role as an auxiliary specificity factor in the initiation of PV 
replication. This process is especially well studied in the case of BPV1 E2. The 
binding of E2TA to its binding sites in the viral origin of replication (ori) is 
responsible not only for tethering of El helicase to ori (Mohr et a l, 1990; 
Sanders and Stenlund, 1998; Sedman and Stenlund, 1995; Yang et a l, 1991), it 
also unmasks the activity of El to bind specifically to ori sequences, through 
inhibiting the competing intrinsic non-specific binding activity of the protein 
(Stenlund, 2003). The N-terminal transactivation domain of E2 is essential for 
the interaction with El and for the functioning of E2 in replication initiation 
(Benson and Howley, 1995; Berg and Stenlund, 1997; Winokur and McBride, 
1996). This domain is functional in the initiation of replication even if tethered 
to BPV1 ori as fused to heterologous DBD (Berg and Stenlund, 1997; Kivimae 
et a l, 2001). The interaction between С-terminal DBD of E2 and El can take 
place, however, if both proteins are bound to adjacent sites on DNA; such 
interaction is facilitating the binding between the N-terminal transactivation 
domain and El (Berg and Stenlund, 1997; Chen and Stenlund, 1998). 
Activation of transcription and replication are carried out by separate determi­
nants of the N-terminal domain, as they can be genetically separated by single 
point mutations (Abroi et a l, 1996; Brokaw et a l, 1996; Ferguson and Botchan, 
1996; Grossel et a l, 1996). E2 may stimulate the viral DNA replication perhaps 
also by additional means, like directly recruiting host replication factors (e.g. 
RPA) to the origin (Li and Botchan, 1993).
BPV 1 E2 protein mediates the attachment of viral genomes to host mitotic 
chromatin and this process is believed to ensure proper nuclear maintenance and 
partitioning of viral genomes in dividing cells (see chapter 3.3). In addition, E2 
proteins of several HPVs have been implicated in cellular processes, which may 
be directly relevant to carcinogenesis. In cervical carcinoma cells, the inte­
gration of high-risk HPV genomes into host genome almost exquisitely disrupts 
the E2 ORF. The ectopic expression of E2 from different PVs in such cells may 
block the cell proliferation (Desaintes et a l, 1997; Dowhanick et a l, 1995; 
Hwang et a l, 1996) and lead to replicative senescence (Goodwin et a l, 2000; 
Wells et a l, 2000) or apoptotic cell death (Desaintes et a l, 1997). Such growth 
inhibitory and apoptotic effects may involve multiple pathways. E2 can repress 
the transcription of viral E6 and E7 genes, the products of which inhibit the 
activity of cellular p53 and Rb tumour suppressors, respectively (see chapter 
2.3.4). As a result, the ectopic E2 over-expression may reactivate growth 
inhibitory and apoptotic signals that are dependent on p53 and Rb. 
E2-dependent apoptosis may also occur independent of the regulation of PV 
gene expression, using both p53-dependent as well as independent pathways
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(Webster et al., 2000; Desaintes et al., 1999). In this context, it is interesting to 
note that HPV16 E2 protein (HPV16)has been shown to interact with p53 
(Massimi et al., 1999) and HPV18 E2 is able to repress human telomerase 
reverse transcriptase promoter (Lee et al., 2002).
2.3.3. Replication protein El
El is the longest among PV ORFs. El proteins encoded by different PVs are 
well conserved both in sequence level as well as on the functional level (Wilson 
et al., 2002). The El of BPV1, biochemically the best described from PV El 
proteins, has the molecular weight of 68kD. In vitro studies have demonstrated 
that it is required for both, initiation and elongation stages of the viral repli­
cation (Gillette et al., 1994; Liu et al., 1995), acting as a DNA-dependent 
ATPase and DNA helicase responsible for the unwinding of ori and subsequent 
replication fork progression (Bream et al., 1993; Hughes and Romanos, 1993; 
Seo et al., 1993; Yang et al., 1993). El can bind to its binding site in the PV ori 
region, but the binding of E l alone is relatively weak and insufficient to provide 
the specificity required in vivo conditions (Ustav et al., 1991; Wilson and 
Ludes-Meyers, 1991; Yang et al., 1993). However, the cooperative binding with 
E2 increases dramatically the efficiency and the ori-specificity of the process 
(Sanders and Stenlund, 2000; Sedman and Stenlund, 1995). As a reflection of 
this, the papillomavirus DNA replication requires both, El and E2 proteins in 
vivo (Ustav and Stenlund, 1991; Ustav et al., 1991), even though El alone is 
sufficient to initiate the replication in vitro where the concentration of El 
protein is higher and the concentration of competing DNA lower than in vivo 
conditions (Bonne-Andrea et al., 1995; Melendy et al., 1995; Muller et al., 
1994). As a first step in the ori recognition process, the El and E2 proteins bind 
cooperatively to its adjacent binding sites in the ori, generating initial E12E22 
complex (Sanders and Stenlund, 1998; Sedman et al., 1997). E2 is then released 
from the complex in the ATP-dependent manner and additional El molecules 
are recruited, eventually leading to the formation of larger complexes that cause 
partial melting of the DNA duplex in ori region (Lusky et al., 1994; Sanders 
and Stenlund, 1998). The final, active complex of El with ATPase and 3’> 5’ 
helicase activity, is formed as a hexameric ring on the single-stranded DNA 
(Fouts et al., 1999; Sedman and Stenlund, 1998). The direct interaction between 
El and E2 proteins, apart from assisting El in viral replication initiation, can 
also modulate the activity of E2. For example, the binding of BPV1 El can 
interfere with the transactivation function of E2 (Ferran and McBride, 1998; 
Sandler et al., 1993) as well as with the binding of E2 to mitotic chromosomes 
(Voitenleitner and Botchan, 2002).
El can interact not only with E2 but also with a number of host cell proteins, 
which can be directly or indirectly linked to the PV replication. BPV1 El can 
bind to the DNA polymerase a-primase (Bonne-Andrea et al., 1995; Park et al.,
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1994) as well as to RPA (Han et a l, 1999), both have been shown to directly 
participate in BPV1 replication (Melendy et a l, 1995; Muller et a l, 1994; Park 
et a l, 1994). The interactions of El with S-phase specific kinase cyclinE/Cdk2 
(Cueille et a l, 1998) and SUMO-1 conjugase Ubc9 (Rangasamy and Wilson, 
2000; Rangasamy et a l, 2000) lead to the covalent post-translational 
modifications of the El protein, phosphorylation and sumoylation, respectively. 
The phosphorylation by cyclinE/Cdk2 seems to be important for the activation 
of the El activity in replication; the sumoylation is required for efficient nuclear 
accumulation of the El protein. In addition, the binding of HPV11 El to histone 
HI (Swindle and Engler, 1998) and HPV 18 El to chromatin modifying factor 
Ini 1/hSNF 5 (Lee et a l, 1999) could reflect the possible link between El- 
dependent replication and modifications of the chromatin structure.
2.3.4. Transforming proteins E5, E6, and E7
Apart from El and E2 initiatory proteins, all the other PV replication proteins 
are ‘borrowed’ from host. As the activity of these proteins is exerted in S-phase 
of the cell cycle, the sustained proliferative state appears to be critical for 
efficient PV replication in differentiating epithelial cells that normally would 
exit from the cell division cycle. To answer these needs, PVs encode for three 
transforming proteins capable of promoting cellular proliferation- E5, E6, and 
E7. However, different papillomaviruses seem to utilise these proteins in 
somewhat different ways.
In contrast to the HPVs, the major transforming protein of BPV1 and other 
fibropapillomaviruses appears to be E5 (DiMaio and Mattoon, 2001). BPV1 E5, 
with its 44 amino acids, is probably one of the shortest oncogenes known. E5 
protein is very hydrophobic and forms homodimers. It is associated with intra­
cellular membranes, localising predominantly to the Golgi complex and 
endoplasmic reticulum (Burkhardt et a l, 1987; Burkhardt et a l, 1989; Burnett 
et a l, 1992; DiMaio et a l, 1986; Schiller et a l, 1986; Schlegel et a l, 1986). 
BPV1 E5 is sufficient for the transformation of rodent cell lines in vitro 
(DiMaio et a l, 1986; Groff and Lancaster, 1986; Rabson et a l, 1986; Schiller et 
al, 1986). The functioning of E5 as an oncogene is achieved through the 
contacts with other cellular membrane proteins and modulation of their activity, 
as E5 itself does not possess any enzymatic activity. It has been shown that E5 
protein can bind to and activate the platelet-derived growth factor (PDGF) ß 
receptor in the absence of exogenous ligand (Petti and DiMaio, 1992; Petti et 
a l, 1991). Such binding correlates well with transformation activity of E5 
(Klein et a l, 1998). BPV1 E5 also binds to the 16-kDa transmembrane channel- 
forming subunit of the vacuolar proton ATPase (Goldstein and Schlegel, 1990; 
Goldstein and Schlegel, 1990) and this binding can lead to the alkalisation of 
the Golgi lumen. Again, the genetic analysis has demonstrated good correlation 
between Golgi alkalisation and transformation by E5 (Schapiro et a l, 2000). E5
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may also function to protect the infected cells from host immune system 
through interfering with the expression and transport of the antigen-presenting 
МНС I complex to the cell membrane (Ashrafi et al., 2002; Marchetti et al., 
2002).
The role of E6 and E7 proteins is more prominent in the transformation by 
different HPVs and both proteins are linked to the development of cervical 
cancer in the case of high-risk HPV types (Mantovani and Banks, 2001; Munger 
et al., 2001; zur Hausen, 2002). Like E5, both E6 and E7 exert their activity 
through interactions with different cellular regulatory proteins. Probably the 
most studied and the most important is the binding of E6 and E7 to tumour 
suppressor proteins p53 and pRb, respectively, which both are capable of 
controlling the cell cycle progression. The binding of E6 to p53 in a complex 
with the cellular ubiquitin ligase E6-AP promotes the degradation of p53 
protein in the ubiquitin-dependent pathway (Huibregtse et al., 1991; Scheffner 
et al., 1993; Scheffner et al., 1990; Wemess et al., 1990). The binding of E7 
inactivates the pRB (Cheng et al., 1995; Dyson et al., 1989; Martin et al., 1998; 
Munger et al., 1989) and promotes its proteolysis (Boyer et al., 1996). 
However, both processes are efficient only in the case of E6 proteins of high- 
risk HPVs, e.g. HPV16 and 18. In the case of low-risk HPV6 and 11, the 
binding of E6 to p53 is unable to induce its degradation (Crook et al., 1991), 
and E7 proteins bind to pRb with a lower efficiency, failing to promote 
transformation as efficiently as E7 of high-risk HPVs (Gage et al., 1990; 
Munger et al., 1989). In the case of BPV1 proteins, there is most likely no direct 
interaction between E6 and p53 as well as between E7 and pRb. It is also 
interesting to note that some of the bovine PV types, namely BPV3, 4, and 6, 
lack the E6 ORF entirely (Jackson et al., 1991).
A number of additional, p53- and Rb-independent possible targets have been 
identified in the case of E6 and E7 proteins, including several members of the 
signal cascades that control the cellular proliferation (Mantovani and Banks, 
2001; Munger et al., 2001). E6 is also able to function through modulating the 
transcription of certain genes, like that encoding for human telomerase reverse 
transcriptase subunit (hTERT) (Gewin and Galloway, 2001; Klingelhutz et al., 
1996; Veldman et al., 2001), and the demonstration of the interaction between 
transcriptional co-factor p300/CBP and HPV 16 E6 has provided possible 
mechanism for such modulation (Patel et al., 1999; Zimmermann et al., 1999).
In summary, the cellular transformation by PV oncogenes E5, E6, and E7 is 
likely to represent a complex process, involving cellular tumour suppressor 
genes p53 and pRb as well as several alternative proteins that may be differently 
targeted by individual PVs in various cellular conditions.
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2.4. BPV1 DNA replication
The basis of viral multiplication lies in the replication of its genome. All three 
stages of the PV life cycle — initial amplification, following stable extra- 
chromosomal maintenance, and vegetative multiplication of the viral genome — 
require the replication of viral DNA to take place. Several studies have 
indicated that alternative replication mechanisms may be used during the 
different stages. In a sense, we can use the term “replication cycle” not only as 
synonymous to life cycle or multiplication cycle of PVs, but also specifically 
referring to the ordered transitions taking place in the replication mechanism of 
viral genome.
2.4.1. El,E2-dependent replication and 
viral extrachromosomal establishing
It is widely acknowledged now, that during the initial extrachromosomal 
establishing stage, BPV1 as well as other PVs use El,E2-dependent replication 
mechanism. The disruption of El or E2 ORF renders the BPV1 genomes unable 
to show any detectable extrachromosomal replication signal after the entry into 
the cell (DiMaio and Settleman, 1988; Ustav and Stenlund, 1991). In transient 
transfection assays, the replication of reporter plasmids that carry PV origin of 
replication (ori) can be achieved only when El and E2 are expressed in the cells 
(Del Vecchio et al., 1992; Remm et al., 1992; Ustav and Stenlund, 1991). The 
interactions between cis-and rrans-elements for replication are surprisingly well 
conserved in the case of different PVs. For example, the El and E2 proteins of 
HPV 11 and BPV 1 can initiate the replication from ori sequences of the same 
viruses in freely mixed combinations in various cell lines, albeit with varying 
efficiency in different combinations (Chiang et al., 1992).
Both cis and trans requirements for El,E2-dependent replication as well as 
first steps of the initiation process have been studied extensively not only in the 
transient in vivo assays, but also in various in vitro systems assembled from 
cellular extracts and purified proteins. As already discussed in previous chap­
ters, the only viral protein participating directly in the replication initiation and 
following elongation stages is hexameric El helicase. E2 works as auxiliary 
recruitment and specificity factor for El. The cellular proteins that are required 
in El,E2-dependent replication of BPV1 overlap in large extent, but not 
entirely, with those required for SV40 replication (Melendy et al., 1995). The 
origin of replication for BPV1 as well as other PVs has been mapped into the 
non-coding URR (LCR) region (Chiang et al., 1992; Del Vecchio et al., 1992; 
Remm et al., 1992; Ustav et al., 1991). The ori functions as the initiation 
complex recruitment zone as well as the region of initial destabilisation of the 
DNA duplex (Howley, 2001). Minimal ori contains El binding site, at least one
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binding site for E2, and adjacent АУТ rich region (Ustav et a l, 1991). The 
function of the binding sites is the initial recruitment of El and E2 proteins, and 
the A/T rich-region facilitates the duplex melting (Stenlund, 1996).
2.4.2. Stable maintenance replication
It is not clear yet, if the El,E2-dependent replication mechanism is required 
only for initial amplification and extrachromosomal establishing of the viral 
genomes, or is basically the same mechanism used also after extrachromosomal 
maintenance has been successfully established. El and E2 are clearly necessary 
for establishing of the extrachromosomal maintenance of the BPV1 URR 
reporter plasmids in the long-term assays (Piirsoo et a l, 1996). However, it has 
been reported recently that even though intact El is required for episomal 
establishing of the BPV1 genomes in mouse С 127 cells, its continuing activity 
seems to be dispensable for already established stable extrachromosomal 
maintenance status (Kim and Lambert, 2002). In the same publication, Kim and 
Lambert also hypothesise that the papillomavirus stable maintenance replication 
might rely entirely on the same factors and complexes, including DNA helicase, 
that replicate host genomic DNA. Some indirect support to this hypothesis 
comes from two separate notions. First, the genomic DNA of BPV 1 as well as 
some HPVs can apparently replicate stably also in Saccharomyces cerevisiae 
cells, and, at least in the case of HPV 16, none of the viral ORFs (including El) 
is essential for this process (Angeletti et al., 2002; Zhao et a l, 2002). Second, 
such use of the cellular replication complexes has been already established in 
the case of two other DNA viruses with prominent latent extrachromosomal 
maintenance stage — Kaposi’s sarcoma associated herpesvirus (KSHV) and 
Epstein-Barr virus (EBV) (Chaudhuri et a l, 2001; Dhar et a l, 2001; Schepers 
et a l, 2001). Despite all this, additional and more conclusive evidence is clearly 
required to clarify this point. For example, the replication of BPV1 genome 
during its stable extrachromosomal maintenance does not follow the strict once- 
per cell-cycle initiation mechanism that would be expected if the cellular 
replication complexes were involved. Such mechanism is used during the 
replication of EBV oriP by cellular machinery, but more relaxed random-choice 
initiation mechanism is used by BPV1 (Gilbert and Cohen, 1987; Ravnan et al.,
1992).
The 2D analysis of replication intermediates (Schvartzman et a l, 1990; 
Yang and Botchan, 1990) as well as electron microscopy analysis of the 
initiation zone (Waldeck et a l, 1984) in stably transformed rodent cells has 
mapped the initiation region into the URR part of the BPV 1 genome. Therefore, 
whatever the replication mechanism, the cis-sequences that participate in the 
initiation of the stable maintenance replication seem to map into the same, 
uncoding URR part of the PV genome, which is used also in the E I n ­
dependent replication initiation. In accordance with this, the URR region is
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sufficient to ensure the establishing of stable extrachromosomal maintenance of 
reporter plasmids in El,E2-expressing cells (Piirsoo et al., 1996).
2.4.3. Papillomavirus vegetative replication
Until recently, the lack of good model systems has hampered the studies on the 
PV replication during the later, vegetative stage. 2D electrophoresis analysis of 
the replication intermediates has indicated that the rolling-circle replication 
mechanism may be involved in the vegetative replication of HPV 16 and HPV31 
(Flores and Lambert, 1997). There are indications that similar mechanism may 
be used also by BPV1 (Burnett et al., 1989; Dasgupta et al., 1992).
2.5. Concluding remarks
Despite almost two decades of concentrated efforts, there is still a lot to be 
clarified about the processes that direct the multiplication of BPV 1 as well as 
PVs in general. The genome structure and specific properties of the viral 
proteins have been characterised quite extensively. On the other hand, there are 
noticeable gaps in the present understanding of how the different viral 
regulatory sequences and protein activities interact with the molecular processes 
operating inside the host cell, and how the proper order and interplay of all 
these interactions is achieved in the viral replication cycle. The continuous 
emergence of new laboratory techniques and better in vitro models for studying 
the full viral replication cycle should provide additional means to find the 
answers to these questions.
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3. RESULTS AND DISCUSSION
3.1. Objectives of the present study
Together with my colleagues, I have tried to find answers to some of the 
questions that concern the virus-cell interactions in the replication cycle of 
BPV 1 and papillomaviruses in general. More specifically, we have made efforts 
to understand the molecular processes that govern the establishing and efficient 
preservation of the stable episomal maintenance of BPV1 genomes in the 
proliferating host cells. The main objectives of the studies that have lead to the 
publications forming the basis of this thesis can be very shortly summarised as 
follows:
1. To look for possible effects of the tumour suppressor protein p53 on the 
papillomavirus replication;
2. To use p53 as a tool for testing the possible utilisation of different replication 
mechanisms during the early stages of BPV 1 life cycle;
3. To investigate the viral factors that determine the efficient nuclear 
maintenance and mitotic partitioning during the stable extrachromosomal 
maintenance of BPV 1 genomes.
3.2. Studies on the effects of p53 
on the papillomavirus replication (I,III)
3.2.1. p53 and viruses — short introduction
Tumour suppressor protein p53 is a central coordinator of the defence 
mechanisms that ensure genetic stability in the metazoan cells. It is built up as a 
typical eukaryotic transcription activator, containing the DNA binding and 
transactivation domains and possessing the ability to activate or repress the 
transcription of certain genes. By modulating the transcription of genes of 
several regulatory proteins in response to different genotoxic stress conditions, 
p53 can prevent the fixation of genetic errors by blocking the transition of cells 
in the cell cycle or inducing the apoptotic death of the damaged cells (Ко and 
Prives, 1996; Vousden and Lu, 2002). For successful propagation, several DNA 
viruses encode for proteins that bind and effectively modulate the activity of 
p53 protein (including PV E6, see chapter 2.3.4), thus counteracting its effects 
on the viral multiplication. It has been shown, for example, that the 
transcriptional activity of p53 is abrogated by the viral oncoproteins ITAg from 
simian virus SV40, E1B 55kD from adenovirus Ad5, and high-risk HPV E6 
proteins (Mietz et al., 1992; Yew and Berk, 1992). p53, in turn, can modulate
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the functions of viral proteins, like the helicase activity of SV40 ITAg (Sturz- 
becher et al., 1988; Wang et al., 1989). p53 can also suppress the replication of 
DNA viruses, like SV40 (Braithwaite et al., 1987) and polyomavirus JCV 
(Staib et al., 1996).
3.2.2. p53 suppresses the amplificational replication 
of the papillomaviruses — what could be the mechanism?
We have studied the effect of p53 expression on the replication of papilloma­
virus origin of replication and found that the over-expression of human p53 can 
suppress the El,E2-dependent amplificational replication of BPV1, HPV 11, and 
HPV 18 ori reporter plasmids in the transient co-transfection assay (I, Fig.lA; 
Ш, Fig.lA). This effect is not dependent on the endogenous p53 background, 
occurring also in the human Saos2 cell-line that does not express any p53 (I, 
Fig.4). The genetic mapping indicated that the parts of p53 protein that are 
required for this activity include the intact central DNA-binding domain, the 
oligomerisation region from С-terminal domain, and part of the N-terminal 
domain containing the RPA-binding and proline-rich sequences. In contrast, the 
first N-terminal 39 amino acids that carry main transactivation activity and also 
С-terminal regulatory domain in the extreme C-terminus (30 amino acids) are 
dispensable for the suppression of PV replication (I, Fig.2; Ш, Fig.l).
Due to our assay conditions, the inhibition of papillomavirus replication by 
p53 could have also been achieved by rather trivial means — through reducing 
the expression levels of the essential viral replication proteins (El and E2), or 
inducing either cell-cycle block or apoptosis. However, we performed several 
control assays with CH04.15 cells and its daughter cell-line CHOBgWO, which 
excluded this possibility. Firstly, none of the three approaches (FACS, TUNEL, 
and BrdU labelling), which we used to analyse the cells processed in the same 
assay conditions as in the parallel transient replication assays, indicated any 
apparent correlation between p53-dependent replication suppression and chan­
ges in the cell growth or viability (I, Fig.6 and Table 1; Ш, Fig.2). As for the 
p53-dependent changes in the El or E2 expression levels, the p53 constructs 
that are capable of inhibiting the PV replication seem also to inhibit the 
expression from the strong promoters of the heterologous viral origin, such as 
cytomegalovirus immediate early promoter (Lepik and Ustav, 2000) and SRa 
(Ш, Fig.ЗА). As we found out, this could have lead to the diminished levels of 
El protein in our assay conditions (Ш, Fig.3A). However, the restoration and 
even the several-fold rise of the El expression above normal endogenous level 
due to the additionally transfected expression construct caused only slight 
rescue of the p53-dependent inhibition of the amplificational replication (Ш, 
Fig.4). Therefore, the sensitivity of PV transient amplificational replication to 
the p53 over-expression cannot be explained solely by reduced level of the 
essential viral replication proteins and reflects most likely the direct effect of the
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p53 protein on the replication. To support this conclusion, the human p53 
protein is able to suppress the El-dependent replication of BPV1 ori reporter 
constructs also in the cell-free in vitro system (Kadaja, M., and Ustav, M., 
personal communication).
We can presently only speculate, what is the exact mechanism of the 
suppression. We know that according to the deletion analysis, this mechanism 
does not require the transcription activation by p53. The inhibitory effect of p53 
on the expression of some cellular replication factor(s) cannot be excluded, but 
is highly unlikely. First of all, such effect of p53 seems to be specific to the 
expression from strong heterologous viral promoters, but not form weaker ones, 
like HSP70 promoter (see the E2 expression on I, Fig.5A; and on Ш, Fig.3A) or 
RSV LTR (Lepik and Ustav, 2000). Moreover, it seems feasible to assume that 
significant decrease in the levels of general replicator factors should have lead 
to the changes also in the host genome replication and cell cycle, but no such 
changes were apparent. In addition, p53 also fails to inhibit the EBNA1- 
dependent once-per-cell-cycle replication of EBV oriP in the conditions where 
it efficiently inhibits the papillomavirus amplificational replication (I, Fig.3). 
Therefore, the effect of p53 on the PV replication is likely to be direct and 
specific, involving both the recognition as well as following steps that are aimed 
to interfere with the replication mechanism. Number of reports has provided 
hints about the activities and interactions of the p53 protein that could be 
potentially involved in this process. p53 can bind to the cellular replication 
factors, like replication protein A (RPA) (Dutta et al., 1993; He et al., 1993; Li 
and Botchan, 1993) and DNA polymerase a (Kuhn et al., 1999). p53 can 
recognise and bind to the lesions in genomic DNA, like single-stranded regions 
(Bakalkin et al., 1995), that are likely to appear not only after various genotoxic 
stresses but also during intensive amplificational replication process. p53 has 
also a 3’>5’ exonuclease (Mummenbrauer et al., 1996) and ssDNA reannealing 
activities (Bakalkin et al., 1994; Brain and Jenkins, 1994; Oberosler et al.,
1993). In addition, the possibility of direct interaction of p53 with viral 
replication proteins cannot be overlooked, as E2 proteins from HPV 16 and 
HPV8 have been shown to interact with p53 (Akgul et al., 2003; Massimi et al., 
1999). However, according to electromobility shift analysis, neither the binding 
of BPV 1 E2 to its specific binding sites on DNA nor the mobility of E2-DNA 
complex are affected by p53 in our assay conditions (I, Fig.5C, and data not 
shown). It has been also suggested that in the case of HPV8, the p53-dependent 
inhibition of replication may be achieved through competitive binding of p53 
and E2 to the overlapping binding sites in viral ori (Akgul et al., 2003). Such 
mechanism is highly unlikely in the case of BPV1, as there are no apparent p53 
binding sites present in the viral minimal ori region.
In addition to the human p53, we have tested also the mouse p53 in 
the transient assays and found that it can function as the suppressor of 
the PV amplificational replication (I, data not shown). We have not tested 
the effect of bovine p53 in these conditions. According to BLAST alignment
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of the respective amino acid sequences from NCBI database 
(http://www.ncbi.nlm.nih.gov), the full-length human p53 carries approximately 
80% amino acid sequence identity with bovine and 77% with mouse p53. 
Therefore, we can expect significant conservation of these p53 proteins also on 
the functional level, including the ability to suppress the amplificational repli­
cation of PVs. On the other hand, the results presented by the colleagues from 
our lab have demonstrated that both human and mouse p53 proteins that 
suppress the replication of BPV1 ori in human and hamster cell-lines, are 
unable to do so in several mouse cell-lines (Lepik and Ustav, 2000). The 
kinetics of El,E2-dependent accumulation of the newly replicated BPV1 ori 
reporter plasmid in mouse cells is roughly similar to that in the human and 
hamster cells. Therefore, the inability of p53 to function in mouse cells most 
likely does not reflect the differences in the replication mode or in the 
replication intermediates, but rather the inability of p53 protein to interact with 
specific target proteins participating in the replication initiation or regulation 
mechanisms.
3.2.3. Two separate replication modes of the BPV1 origin 
of replication that have different sensitivity to p53 — 
possible implications of this observation on the BPV 1 life-cycle
According to our transient replication assays, p53 is unable to interfere with the 
EBNA1-dependent once-per-cell-cycle replication of EBV oriP in the 
conditions where it efficiently inhibits the papillomavirus amplificational repli­
cation (I, Fig.3). This suggested us that only the ‘uncontrolled’ amplificational 
replication is sensitive to p53 action. We became curious about the effect of p53 
on BPV 1 stable maintenance replication, which has characteristics of both its 
own amplified replication (random choice initiation) as well as the replication 
of oriP (the overall synchrony with host genome duplication). In our lab, we 
have established a CHOBgMO cell-line as a simplified model system for 
studying the basic processes of replication and nuclear maintenance during 
BPV1 latency (Piirsoo et al., 1996). This cell-line expresses constitutively viral 
El and E2 proteins from chromosomally integrated cassettes and maintains 
stably episomes of the BPV1 URR reporter plasmid pNeoBgl40. Thus, only 
very minimal viral cis (URR) and trans (El, E2) determinants required for the 
establishing of the BPV1 stable maintenance are present in this well-defined 
model.
Despite of the already present stable maintenance replication of the BPV 1 
URR reporter plasmid in these cells, the transient transfection of similar reporter 
into CHOBgMO cells leads to the initial amplificational replication of the newly 
transfected reporter. Therefore, using the panel of p53 mutant versions already 
tested in previous transient replication assays (I, Fig.2), we could make sure that 
p53 is able to function as a repressor of the BPV1 ori-dependent replication in
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this cell-line (Ш, Fig.l). Note that we have disained the input URR reporter to 
contain one additional HindlH site compared to the stably maintained one. 
Because of that, the digestion with Hindffi linearises stably maintained reporter, 
but gives ~lkb shorter fragment in the case of amplificationally replicating 
input reporter. The respective fragments can be separated on the agarose gel 
electrophoresis and analysed by Southern hybridisation after transferring to 
nylon membrane.
We then proceeded to analyse the possible effect of p53 on the BPV 1 stable 
maintenance replication in these cells, using the transient transfection assay that 
was slightly modified in order to get rid of the ‘background’ signal coming from 
non-transfected cells lacking p53 expression. The results of these experiments 
demonstrated that the truncated version of p53 (N39C362), which contains a 
minimal set of domains required for replication suppression activity, fails to 
inhibit the stable maintenance replication of BPV 1 URR reporter in CHOBgMO 
cells (Ш, Fig.3). This construct inhibits efficiently the simultaneous transient 
amplified replication of the input BPV 1 URR reporter in these cells. Therefore, 
these two BPV 1 URR-dependent replication modes — initial transient amplifi­
cational replication and stable maintenance replication — have different 
sensitivity to p53.
These data raise two main questions: first, what significance could have the 
observed phenomenon in the BPV1 life cycle; and second, what are the 
differences between these replication mechanisms that are reflected in their 
different sensitivity to p53. The transient El,E2-dependent replication assay 
mimics the initial amplificational replication stage, which is required for 
successful extrachromosomal establishing of the BPV1 genomic DNA after 
infection. We can assume that the uncontrolled over-replication is not favou­
rable for virus, as it could induce the cellular responses leading to cell-cycle 
block or apoptosis. The period of initial quick rise of the copy number per cell 
is apparently considerably shorter in the case of full-length BPV1 genome in 
С127 cells than it is in the case of BPV1 ori plasmids with El and E2 
additionally со-expressed from strong heterologous promoters (Ustav and 
Stenlund, 1991). The possible reason for that is a tight control of the levels of 
El and E2 transcription from viral promoters upon the initial amplification, 
which in turn could normally limit the frequency of replication initiation. It 
could also explain, how BPV1 could establish itself in p53-expressing cells, 
even though its E6 protein, unlike that of high-risk HPVs, is unable to induce 
the degradation of p53 protein in ubiquitin-dependent proteolysis pathway (see 
chapter 2.3.4). The ability of p53 to suppress the amplificational replication 
process might be used by virus in order to apply some additional control on its 
initial amplification, if usual viral control mechanisms fail. In addition, p53 
might also suppress the replication of already established stably maintained viral 
genome molecules that for some reason re-initiate uncontrolled amplification.
Our data also suggest that the mechanisms of initial transient amplificational 
replication and following stable maintenance replication of BPV 1 are likely to
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differ from each other. We found that the simultaneous amplificational 
replication of the BPV1 URR reporter does not affect the efficiency of the 
stable maintenance replication of similar reporter in the same CHOBgl4C) cells. 
Assuming that stably maintained URR plasmids are picked randomly from total 
pool for replication initiation (Piirsoo et al., 1996), we can conclude that the 
transiently replicating URR plasmids are not included into stably replicating 
pool. It means, that stably replicating URR reporter plasmid episomes form a 
population that is somehow separated from amplificationally replicating input 
reporter population. This separation is bound to more tightly regulated 
replication initiation mechanism and requires certain establishing stage to be 
passed in order to occur. The differences between control mechanisms of 
amplificational and stable maintenance replication are clearly emphasised by 
altered sensitivity towards p53. The El-independent replication mechanism, 
discussed in chapter 2.4.2, could be one of the potential explanations to such 
mechanistic differences between BPV1 amplificational and stable replication. 
The fact that neither the p53-dependent down-regulation of the El expression 
nor the additional over-expression of El (Ш, Fig.4.) in CHC)Bgl40 cells 
affected the copy number of stably maintained BPV1 URR reporter in our 
experiments seems to support this speculation. However, there is also an 
alternative explanation to this observation — the replication of stably 
maintained reporter may depend on E l, but its level in CHOBgMO cells is much 
higher than actually required for the replication of the reporter. Consequently, 
the frequency of replication initiation and the copy number of stably maintained 
reporter might be determined not by El level in these cells, but by other factors.
The long-term stable maintenance of BPV1 replicon is likely to be 
dependent on its non-covalent attachment to host chromatin, and this process 
has been linked to efficient partitioning and nuclear retention of the viral 
genomes during mitosis (see chapter 3.3). We can speculate that the sub-nuclear 
localisation of BPV 1 genomic DNA could be important also for the regulation 
of its replication initiation, as the association with chromatin could enable the 
access to the replication control mechanisms operating during the host cell 
genome replication. Different p53 sensitivity could appear as an indirect 
consequence of the altered sub-nuclear localisation, as it may be responsible for 
the changes in replication mechanism of the viral DNA that are differentially 
recognised and affected by p53. In addition, the sub-nuclear localisation of the 
viral replication process could perhaps be directly linked to the altered p53 
sensitivity, as different sub-nuclear compartments could have different 
accessibility to p53.
In conclusion, our data suggest that BPV1 can use different replication 
modes for initial transient amplification and during the following stable 
maintenance stage. As these two replication modes have different sensitivity to 
p53, the elucidation of specific targets of the p53 protein could provide a 
convenient tool for defining the differences between these replication modes on 
the molecular level.
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3.3. Studies on the viral factors that determine 
the long-term episomal maintenance 
of the BPVI genome (II)
Efficient extrachromosomal maintenance of the DNA viruses in proliferating 
host cells requires the viral genome replication and partitioning between 
daughter cells to proceed in the overall synchrony with the maintenance cycle of 
the host genome. Because of their relatively small genomes, the episomal DNA 
viruses, unlike the cellular chromosomes, cannot afford to carry long and 
complex centromeric regions that could ensure the proper partitioning and 
nuclear retention functions during mitosis. Some other strategy has to be used 
instead.
In the case of BPV1, as already discussed in previous sections, the URR 
region carries all the cis-tlements required for the establishing of stable 
extrachromosomal maintenance in El,E2-expressing cells. These elements 
consist of the minimal origin of replication and additional E2 binding sites, the 
latter forming a so-called minichromosome maintenance element (MME). Suffi­
cient number of high affinity E2 binding sites is critical for proper MME 
function (Piirsoo et al., 1996). The function of E2 binding sites (MME) in the 
stable episomal maintenance process was not clear in the beginning. The first 
insights were provided by two publications, which showed that BPV 1 genomes, 
as well as E2 protein, are tethered to the host mitotic chromosomes in С 127 
mouse fibroblasts, and that mutations in E2 and El encoding regions are able to 
affect such localization (Lehman and Botchan, 1998; Skiadopoulos and 
McBride, 1998). These data gave us the idea to test if the chromosome locali­
sation of BPV 1 is mediated by its E2 protein and MME, and if such localisation 
can be linked to the stable maintenance function of the MME.
We used the fluorescent in situ hybridisation (FISH) to test the localisation 
of the stably maintained BPV1 URR reporter plasmid in mitotic CHOBgMO 
cells. The results of these experiments demonstrated that the URR reporter is 
distributed on mitotic chromosomes following speckled and obviously random 
pattern (П, Fig.2 panel A), which resembles the chromosomal localisation 
pattern of full-length BPV 1 genomes according to earlier studies (Lehman and 
Botchan, 1998; Skiadopoulos and McBride, 1998). The number of URR 
reporter-specific dots in the CHOBgMO cells was approximately in the same 
range (10-50 per nucleus) as its previously determined copy number in this cell- 
line (Piirsoo et al., 1996), suggesting that the FISH analysis was sensitive 
enough to detect single plasmid molecules. Similar pattern was observed also in 
the case of CH04.15 and CH049 cells (expressing El and E2, or E2 only, 
respectively) that were transiently transfected with URR reporter (П, Fig.2 panel 
B; Fig.4 panel A). No signal was observed if CHO cells, which do not express 
E2, were transfected with URR reporter. These data demonstrated first of all, 
that BPV 1 URR carries all the necessary c/s-elements for chromatin attachment,
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and E2 protein is the only viral trans-factor that is necessary for this process. 
Another interesting observation from these studies was that the E2 and URR 
dependent chromatin attachment does not seem to require a prolonged establi­
shing period in order to occur. The analysis was performed around 48hrs after 
transfection, by which time the cells had barely passed through one cell cycle. 
We could also say that the chromatin attachment is not affected by moderate El 
co-expression. Later it was shown, however, that El can titrate E2 out of 
chromatin, but only on much higher E1:E2 ratios (Voitenleitner and Botchan, 
2002).
The following genetic dissection demonstrated that the E2 binding sites 
(MME) from URR determine its ability to be tethered to chromatin in E2 
protein dependent fashion (П, Fig.2). The El binding site (and thus the 
replication ability) as well as other sequences in the URR are dispensable for 
the chromatin attachment function (П, Fig.2). Our data provided also evidence 
about the link between MME, chromatin attachment, and efficient stable 
maintenance, as none of the reporter constructs lacking intact MME and unable 
for stable episomal maintenance was tethered to mitotic chromosomes (П, Fig.2; 
Fig.7). In conclusion, we demonstrated that MME exerts its role in episomal 
minichromosome maintenance of the BPV1 genome through the viral E2 
protein mediated association with the host cell chromatin. Therefore, the BPV1 
stable episomal maintenance consists of two main functions- chromatin attach­
ment, which is likely to provide proper partitioning and nuclear retention to the 
viral genomes, and replication, which is responsible for compensation of the 
plasmid loss during host cell divisions.
It is easy to imagine that the tethering to host chromatin could provide the 
means for viral genome partitioning and nuclear retention, through a ‘piggyback 
ride’ during the mitotic separation of host chromosomes to daughter cells. In 
addition, as already discussed in the chapter 3.2.3, the chromatin association 
could perhaps also provide the access to cellular replication control mechanisms 
that help to establish the viral genome copy number control during stable 
episomal maintenance. It should be noted, however, that the BPV1 MME- 
dependent chromatin attachment has been so far conclusively demonstrated 
only in mitotic cells and the data are lacking about the maintained chromatin 
localisation during S-phase. The utilisation of chromatin attachment to ensure 
the stable episomal maintenance is not unique to papillomavirus family, but, 
paradoxically, is also not necessarily common mechanism inside this family. 
Two gammaherpesviruses with prominent latent phase in their life cycle — 
EBV and Kaposi’s sarcoma associated Herpesvirus (KSHV) — use similar 
means for their extracromosomal maintenance in dividing cells. Like in the case 
of BPV1, the single viral protein acts as a molecular linker between viral 
genome and host chromatin: EBNA1 in the case of EBV (Kanda et al., 2001), 
and LANAI in the case of KSHV (Ballestas et al., 1999). On the other hand, the 
minimal number of E2 binding sites in BPV1 URR sufficient to provide the 
minichromosome maintenance function (Piirsoo et al., 1996) exceeds the
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number of these sites generally found in URR of different HPV types. It is 
possible, therefore, that these HPVs may use additional cellular factors to 
ensure the chromatin attachment of their genomes, or use maybe entirely 
different strategy for their efficient extrachromosomal maintenance. Further 
studies are clearly needed to clarify this point.
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CONCLUSIONS
1. p53 suppresses the transient amplificational replication of different 
papillomavirus ori constructs in various human and hamster cell lines. The 
suppression reflects most likely the direct effect of p53 on the papilloma­
virus amplificational replication and does not require N-terminal trans­
activation as well as С-terminal regulatory domains of the protein. On the 
other hand, p53 is unable to interfere with the once per cell-cycle replication 
of Epstein-Barr virus oriP in similar transient transfection assays.
2. The transient amplificational replication of BPV1 URR reporter plasmid can 
take place in cells that already maintain stably extrachromosomal copies of 
similar reporter plasmid. The copy number of stably replicating plasmid is 
unaffected by the simultaneous transient amplification of similar reporter 
plasmid and stable maintenance replication is also insensitive to p53. It 
suggests that the initial amplificational- and following long-term stable 
maintenance replication of BPV 1 are using two clearly different 
mechanisms.
3. The BPV1 URR reporter plasmids are tightly associated with the mitotic 
chromosomes if maintained as stable episomal plasmids as well as in 
transient transfection experiments. E2 binding sites inside BPV 1 URR have 
been shown to form a minichromosome maintenance element (MME), 
which, together with the minimal origin of viral replication, are sufficient 
ds-requirements for establishing of the BPV1 stable maintenance in El, E2- 
expressing cells. We found that the role of MME in this process is to ensure 
the E2-dependent chromatin tethering. The El binding site (and thus the 
replication ability) as well as other sequences in the URR are dispensable for 
the chromatin attachment. There is a clear link between MME, chromatin 
attachment, and efficient stable maintenance, as none of the reporter 
constructs lacking intact MME and unable for stable episomal maintenance 
was tethered to mitotic chromosomes. The E2-mediated association of the 
viral genomes with nuclear chromatin is likely to guarantee the proper 
partitioning and nuclear retention of BPV1 genomes in dividing cells; it can 
perhaps also ensure the optimal exposure of viral DNA replication process to 
the cellular control mechanisms during S-phase.
4. The successful establishing of the BPV1 stable extrachromosomal main­
tenance involves the E2-dependent partitioning mechanism as well as 
specific changes in the replication mechanism of the viral DNA. Therefore, 
the BPV1 stable episomal maintenance seems to consist of two main 
functions — chromatin attachment, which provides proper partitioning and 
nuclear retention to the viral genomes, and controlled replication function, 
which is responsible for sufficient compensation of the plasmid loss 
occurring as a result of host cell divisions.
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KOKKUVÕTE
Papilloomiviirused (PV) on perekond väikeseid kaheahelalise DNA genoomiga 
epiteeliomaseid viirusi. Neid iseloomustab pikaajalise vaikioleku võime alus- 
epiteeli paljunevates rakkudes ja nad on suutelised perioodiliselt põhjustama 
nakatunud kudedes healoomulisi vohandeid- soolatüükaid ja kondüloome. 
Mõned inimese PV tüübid on seotud ka pahaloomuliste emakakaela kasvajate 
tekkega.
Käesoleva doktoritöö aluseks olevates teadusartiklites olen koostöös oma 
kaastöötajatega uurinud seda, milliseid vahendeid kasutavad PVd tõhusaks 
peremeesrakus püsimiseks. Uurimismudelina oleme kasutanud veise papil- 
loomiviirust BPV1. BPV1 genoomi sisenemisele rakku järgneb tema võimen­
datud replikatsioon peremeesraku tuumas, mille käigus valmistatakse kiiresti 
terve hulk viiruse genoomi koopiaid. Osa neist koopiatest seab end jagunevates 
peremeesrakkudes püsivalt sisse kromosoomiväliste rõngasmolekulidena, mille 
koopiaarv raku kohta hoitakse ühtlastes piirides. Püsiva koopiaarvu tagamiseks 
peab viirus kontrollima nii enda genoomi juurdekopeerimist kui tagama värskelt 
paljundatud viirusgenoomide võrdse jaotamise tütartuumade vahel pere­
meesraku pooldumise käigus. Meie katsete tulemused näitavad, et BPV1 
esialgne võimendatud replikatsioon on alla surutav kasvajasuppressorvalgu p53 
poolt; samas stabiilse kromosoomivälise püsimise käigus toimuv replikatsiooni- 
mehhanism ei ole p53-le tundlik. Esialgne võimendatud replikatsioon on 
suuteline toimuma rakkudes kus põhimõtteliselt samasugune viiruspõhine 
replikon juba stabiilselt replitseerub. Selline koosreplikatsioon ei mõjuta stabiil­
selt püsiva replikoni koopiaarvu. Nende tulemuste põhjal võib järeldada, et üks 
ja seesama BPV1 replikon on võimeline kasutama oluliselt erinevaid replikat- 
sioonimehhanisme oma sisseseadmise käigus peremeesraku tuumas ja sellele 
järgneva stabiilse püsimise tarbeks.
Nii meie kui teiste teaduslaborite jõupingutuste tulemusena on selgunud, et 
BPV1 genoomide enam-vähem võrdselt tütartuumade vahel jagunemine pool- 
duvas peremeesrakus toimub peremehe kromosoomidele kinnitumise kaudu. 
Kromosoomidele kinnitunud viirusgenoomi molekulid transporditakse mitoosis 
koos peremehe kromosoomidega tütarrakkude tuumadesse. Meie uurimused 
selgitasid, et selliseks kromosoomidele kinnitumiseks on viiruse poolt vajalikud 
ja piisavad viirusvalk E2 ja küllaldane arv tema seondumiskohti viiruse 
genoomis. Seega avaldub E2 seondumiskohtadele eelnevalt omistatud roll 
BPV1 stabiilses peremeesrakus püsimises just läbi tema võime vahendada 
viirusgenoomide seondumist tuumakromatiinile. Võimalik, et sellise kinnitu­
mise abil tagatakse ka viiruse replikatsiooni kontroll, kuna tekib parem ligipääs 
raku enda genoomi replikatsiooni kontrollmehhanismidele.
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p53 protein was able to block human and bovine papillomavirus DNA amplificational replication while not 
interfering with Epstein-Barr virus oriP once-per-cell cycle replication. Oligomerization, intact DNA-binding, 
replication protein А-binding, and proline-rich domains of the p53 protein were essential for efficient inhibi­
tion, while the N-terminal transcriptional activation and C-tcrminal regulatory domains were dispensable for 
the suppressor activity of the p53 protein. The inhibition of replication was caused neither by the downregu- 
iation of expression of the E l and E2 proteins nor by cell cycle block or apoptosis. Our data suggest that the 
intrinsic activity of p53 to suppress amplificational replication of the papillomavirus origin may have an 
important role in the virus life cycle and in virus-cell interactions.
Human papillomaviruses (HPVs) are small DNA viruses 
clearly associated with the induction of cancer. The papilloma­
virus life cycle can be divided into three stages (7, 20). First, 
following initial entiy, the papillomavirus genome is amplified 
in the nucleus and viral copy number is increased up to 1,000 
per haploid cell genome. During the second, maintenance 
stage, the viral DNA replicates in synchrony with the cellular 
DNA, at a constant copy number per cell. The third, vegetative 
replication stage of the viral genome occurs in the terminally 
differentiated cells. Papillomaviruses have developed an effi­
cient system for modulating the activity of cellular tumor sup­
pressor genes. HPV type 16 (HPV-16) and HPV-18 E6 pro­
teins are capable of interacting with p53 and directing its 
degradation (50), while the E7 protein forms a complex with 
retinoblastoma protein (pRB) (15). These events lead to the 
loss of cell control over crucial events—-DNA replication, re­
pair and apoptosis—therefore creating favorable conditions 
for rapid viral DNA amplification and establishment of infec­
tion. In addition, expression of the E6 and E7 proteins may be 
an indication that some stages of papillomavirus replication 
during the three-step life cycle are susceptible to the action of 
p53 or pRB.
The tumor suppressor protein p53 is believed to be one of 
the key players in the control of the genomic stability of the 
cells (25, 27, 32). It is structured as a typical eukaryotic tran­
scription activator which contains DNA-binding and transacti­
vation domains and is able to activate or repress the transcrip­
tion of certain genes (for a review, see reference 25). Exposure 
of normal cells to different stress conditions induces both an 
intracellular increase in the steady-state level of p53 and direct 
activation of the protein (23). As a result, the transition of cells 
in the cell cycle may be prevented, and apoptotic death of the 
cells with damaged DNA may be induced (reviewed in refer­
ence 32).
Several studies found that the mutation or loss of one or 
both alleles of p53 was sufficient to allow gene amplification to 
occur in the cells (36, 67), thus indicating that the p53 protein 
is involved in the control of events leading to the amplification
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of genomic sequences. The p53 protein seems to be directly 
involved in the control of DNA replication and repair (for 
reviews, see references in reference 25). It has been demon­
strated that the p53 protein is capable of interacting with 
several proteins and enzymes involved in DNA repair or rep­
lication, such as single-stranded DNA (ssDNA)-binding repli­
cation protein A (RPA) (14, 33), cellular DNA helicases (47), 
and homologous recombination factor RAD51/RecA (53). 
The p53 protein lacking its С-terminal regulatory part blocks 
nuclear DNA replication in the transcription-free Xenopus egg 
extracts (13). Immunostaining studies show colocalization of 
the p53 protein with proliferating cell nuclear antigen (PCNA), 
DNA polymerase a, DNA ligase, and RPA at the sites of DNA 
replication in herpes simplex virus-infected cells (62). Repli­
cation of simian virus 40 (SV40) DNA can be prevented by 
binding to and inactivating the large T antigen by the p53 
protein (52, 60). Replication of the polyomavirus origin is 
inhibited by p53 in vitro when up to 16 copies of the p53- 
specific binding sites have been inserted into the plasmid (39), 
while replication of the polyomavirus origin in vivo is activated 
by the same protein in a sequence-dependent manner (22).
We studied the effect of the p53 protein on the replication of 
papillomavirus origins in vivo in different cell lines and found 
that the p53 protein is a potent repressor of bovine and human 
papillomavirus amplificational replication. The repression of 
replication was dependent on the p53 protein concentration in 
the cells. We show that the intact central DNA-binding domain 
and the oligomerization domain of the p53 protein, as well as 
a part of the N-terminal domain containing the RPA-binding 
and proline-rich sequences, are essential for this activity. In the 
same time, the p53 protein and its mutants were unable to 
interfere with the once-per-cell cycle replication of Epstein- 
Barr virus (EBV) oriP. Repression of papillomavirus DNA 
amplification is neither an indirect consequence of the p53- 
dependent cell cycle block or apoptosis nor mediated by the 
transactivation or transrepression activities of the p53 protein. 
Possible implications of the observed phenomena on virus-cell 
interactions will be discussed.
MATERIALS ANI) METHODS
l’lasmids. Bovine papillomavirus lypc 1 (BPV-1) El expression vcctor 
pCGEag, E2 expression vector pCGE2, minimal replication origin plasmid 
pUCAIu, HPV-11 El expression vector pMT2-El, HPV-11 E2 expression vector
6822
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pMT2-E2, and HPV-11 upstream regulatory region (URR)-conlaining plasmid 
p7072-99 have been described previously (11,57). pNeoBgMO contains the BPV- 
I-URR from nucleotides 6446 to 63 and has been described previously (44). The 
LSPV-1 origin constructs pUC12B and pUC18A have been described previously 
(55). The HPV-18 El and E2 expression vector pCGElB and origin plasmid 
pLCR have been reported earlier (45). Plasmid p994 harboring the EBV latent 
oriP is a kind gift of B. Sugdcn (24). Bcl-2 expression plasmid peDBCL2 has been 
described by Mah et al. (37).
Human p53 cDNAs were cloned into expression vector pCG (54). pCG\vtp53 
and pCGlrp248 encode wild-type (wt) and Arg248Trp mutant p53 proteins, 
respectively. The mutant Arg248Trp p53 cDNA was kindly provided by Bert 
Vogelstein. All deletion mutants were created by PCR and expressed from 
the pCG vector. pCGAN39 encodes wt p53 protein with deletion of the first 
34 amino acids. pCGAC362 and pCGA3()5 encode truncated proteins with slop 
codons al positions 362 and 305, respectively. pCGA324-355 encodes p53 with 
deletion of amino acids al residues 324 lo 355. pCGAN3‘MC362 ami 
pCGAN39AC362lrp248 encode wild-type or Arg24XTrp mutanl p53 starting 
from amino acid 40 and containing a stop codon at position 362. AN61ДС362 and 
AN92AC362 lack the first 61 and 92 N-temiinal amino acids, respectively, and 
contain a stop codon at position 362. ДРгоАС362 and Д№9ДРгоДС362 lack 
amino acids 63 lo 91 and contain the stop codon at position 362; 
ДЫ39ДРгоДС362 lacks also the N-terminal 39 amino acids. The correctness of 
the endpoints and all mutated sites of the p53 coding regions were verified by 
sequencing.
Cells and transfections. The cell line CHO and its derivatives CH04.15 
(expressing BPV-1 El and E2 proteins), CHOBgMl) (in addition containing 
latent BPV-1 origin plasmid), and CH0212 (expressing BPV-1 El) (44) were 
maintained in Ham's F12 medium supplemented with 10% fetal calf serum. 
Human osteosarcoma 143 (66), Cos7, and SAOS-2 cells were maintained in 
Iscove’s modified Dulbecco’s medium with 10% fetal bovine serum. Electropo­
ration experiments were carried out as described earlier, using an Invilrogen 
EleclroPorator al capacitance setting 960 |xF. Voltage settings were 230 V for 
CHO, CH04.15, and CHOBgl4t) cells, 170 V for human osteosarcoma 143 cells, 
180 V for Cos7 cells, and 210 V for SAOS-2 cells. Transfection efficiencies were 
determined by in situ staining of the cells transfected in parallel with the ß-ga- 
laclosidasc-exprcssing plasmid pON260 (56). Transient replication assays were 
performed as described previously (56).
Immunoblotting and UNA binding assays. The expression level of p53 mutant 
proteins was estimated by Western blot analysis of CH04.15 cells transfected 
with 500 ng of p53 expression plasmid and processed 24 or 48 h after transfection 
according to standard methods (48). Equal amounts of total protein were ana­
lyzed in each experiment. Antibodies pAb240, pAb421, and pAblSOl were used 
for detection of p53 proteins. The E2 protein level in CH04.15 cells in the 
presence of expressed p53 constructs was analyzed in the same way, using a 
mixture of purified monoclonal E2-specific antibodies 1E2.3F 12,1H10,1E4, and 
3C1 (2). Goat anti-mouse antibody conjugated to alkaline phosphatase was used 
as a secondary antibody.
The effect of p53 expression on E2-spccific DNA-binding activity in CH04.15 
cells was measured as described earlier (2). Analysis was performed 48 h after 
transfection with p53 expression plasmids. p53-specifie DNA binding was tested 
by an analogous protocol, using the artificial p53-binding double-stranded oli­
gonucleotide 5'AGACATGCCTAGACATGCCT3' (21). Monoclonal antibod­
ies pAb421 and 3F12 were added for supershifting the p53-specific and E2- 
specifie complexes, respectively. Monoclonal antibody H07.1 was used for p53 
deletion mutants lacking the pAb421 epitope.
Northern blotting of El inRNA. CH04.15 cells were transfected with 500 ng of 
p53 expression constructs, and 48 h later the total RNA was extracted by using 
an RNcasy Total RNA kit supplied by Qiagen. Northern blot analysis of the 
extracted RNA was performed according to standard methods (48). El-specilic 
radioactive probe was generated by random priming using the 1.8-kb Xlnil- 
£<x>911 BPV-1 El-encoding fragment from pCGEag (57) as a template. El- 
specific signals were quantitated on a PhosphorlmagerSI (Molecular Dynamics), 
and the results were normalized to S7- and ß-actin-specific signals. Human 
ribosomal protein S7 (3) and ß-actin cDNA plasmids used as a templates lo 
generale radioactive probes were kind gifts of Tarmo Annilo and Mati Reeben, 
respectively.
Analysis of cell cycle distribution and sub-G, DNA content of p53-transfected 
CH04.15 cells. Both floating and adherent cells were collected 48 h posllrans- 
fection, washed once with phosphate-buffered saline (PBS), and fixed in 5 ml of 
ice-cold 70% ethanol for How cytometric analysis. The propidium iodide fluo­
rescent staining of nuclei was analyzed in an ATC3000 flow cytometer (Odam- 
Brucker, Wissembourg, France) equipped with a Spectraphysics argon laser. 
Cells were pelleted prior lo the analysis, washed once in PBS, suspended in 500 
M-l of PBS with 1 mM MgCL and 30 pug of RNasc A per ml, and incubated al 37°C 
for 1 h to digest cellular RNA. Propidium iodide was added to a final concen­
tration of 10 ng/ml, and samples were incubaled on ice for al least 15 min to slain 
the nuclear DNA. The signals from 50,000 cells were collected from each sample 
and analyzed by the method of Dean and Jett (13a), using the standard software 
provided by the manufacturer of the flow cytometer. Cells for the parallel 
replication assay were processed as described above. The terminal deoxynuclc- 
olidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay was 
performed as described in reference 17.
RESULTS
p53 protein inhibits amplificational replication of papillo­
mavirus origins. We have developed an efficient model system 
to study the replication of papillomavirus origins in tissue cul­
ture (11, 44, 45,56). To determine whether the p53 protein has 
any effect on the replication, we performed transient replica­
tion assays in CHO-K1 cells, where BPV-1 and HPV origin- 
containing plasmids replicate in the presence of homologous 
and heterologous E l and E2 proteins (11, 57). CHO cells have 
been used extensively for DNA amplification studies and have 
been shown to carry the defective p53 gene with substitution 
Thr211Lys (28). Inspection of these cells with a mixture of 
p53-specific antibodies did not reveal any detectable endoge­
nous expression of the p53 protein in our hands (data not 
shown).
Cotransfection of the BPV-1 E l and E2 expression plasmids 
with the BPV-1 origin plasmid into CHO cells resulted in 
robust replication (Fig. 1A, lane 1). Coexpression of human wt 
p53 protein suppressed BPV-1 origin replication almost com­
pletely in this system (Fig. 1A, lane 2). The extent of suppres­
sion was proportional to the amount of introduced p53 expres­
sion plasmid (Fig. IB) and was detected at 25 ng of the 
cotransfected plasmid DNA. The effects of p53 protein expres­
sion on the replication of the HPV-11 (Fig. 1A, lanes 3 and 4) 
and HPV-18 (lanes 5 and 6) origin plasmids in the presence of 
the homologous E l and E2 replication proteins were identical. 
The replication signal of the HPV origins in CHO cells de­
creased for the third time point (96 h posttransfection), possi­
bly as a result of the less intense replication and the loss of E l 
and E2 expression plasmids from the cells upon cell division. 
Cotransfection with the vector carrying no p53 sequences did 
not affect replication of the papillomavirus origin (Fig. 1A 
lane 7), which indicates that the block of replication is not 
caused by promoter competition between the p53, E l, and E2 
expression cartridges. Experiments carried out with mouse wt 
p53 protein gave identical results (data not shown).
In the next step, we studied the effect of p53 on the repli­
cation of different BPV-1 origin deletion mutants in the cell 
line СН04.15. This cell line exhibits constitutive expression of 
BPV-1 E l and E2 replication proteins from the integrated 
expression vectors (44). Figure 1C represents replication of the 
BPV-1 full-length origin plasmid pNeoBgMO and of origin de­
letion variants pUCAlu, pUC12B, and pUC18A in the absence 
and presence of overexpressed p53 protein. Our data show that 
the replication of plasmids pNeoBgl40, pUCAlu, pUC12B, and 
pUC18A (depicted schematically in Fig. ID) is efficiently 
blocked by the overexpressed p53 protein (Fig. 1C, lanes 2, 4, 
6, and 8) and suggest that there are no defined p53-specific cis 
elements in the BPV-1 origin of replication that could mediate 
the effect, unless it is the minimal replication origin itself: 
A/T-rich region and E l- and E2-binding sites.
Structural determinants of the p53 protein responsible for 
inhibition of amplificational replication of the BPV-1 origin. 
To map the domains of the p53 protein responsible for the 
inhibition of papillomavirus replication, a set of p53 mutants 
was constructed (schematically depicted in Fig. 2A). The sta­
bility, expression level, and activity of the mutant proteins were 
tested in CH04.15, Cos7, and SAOS-2 cell lines by Western 
blot and specific DNA band shift analysis. The mutant proteins 
with the deleted N-terminal activation domain were expressed 
at an approximately fivefold-higher level than proteins with the 
intact N terminus, wt p53, ДС305, ДС362, and ДРгоДС362. 
The N-terminal activation domain contains the binding site of 
the Mdm2 protein, which has been shown to facilitate degra­
dation of the p53 protein in vivo and therefore reduce the
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ing to the artificial p53-binding site (21). The intensity of the 
band shift correlated with the expression level of the p53 pro­
teins in the extract (data not shown).
The BPV-1 origin plasmid and the different mutant p53 
protein expression plasmids were cotransfected into CH04.15 
cells; episomal DNA was harvested and analyzed by Southern 
blotting (Fig. 2B). wt p53, the С-terminal regulatory domain- 
defective mutant ДС362, the N-terminal deletion mutant ДЮ9 
lacking the transcription activation domain, and the double­
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FIG. I. Southern blot analyses. p53 suppresses the amplificational replication 
of different papillomavirus replication origins. Episomal DNA was extracted 
from cells at 48, 72, and 96 h after transfection and digested with restriction 
endonucleases /VI and DprtX. Filters were probed with radiolabeled HPV-11 
URR containing plasmid p7072-99. M, 2(1(1 pg of the linear HPV-11 origin 
plasmid marker; carrier, mock-transfected cells. Arrows indicate the bands gen­
erated after digestion of the episomal BPV-1 origin plasmid with A/I. (A) Effect 
ofwl p53 expression on the transient replication of BPV-1, HPV-11, and HPV-IX 
full-length origin plasmids in CHO cclls. In this assay, KM) ng of BPV-1 origin 
pNeoBgl40 (lanes I and 2), HPV-11 origin p7072-99 (lanes 3 and 4), or HPV-18 
origin pLCR (lanes 5 and 6), with (+ ) or without (—) 1(H) ngof wt p53 expression 
construct pCGwtp53, was transfected. pCGE5AS, control with plasmid produc­
ing no p53 (lane 7). Amounts of El and E2 expression vectors used were 250 ng 
for BPV-1 (pCGEag and pCGE2), 500 ng for HPV-11 (pMT2-El and pMT2- 
E2), and 650 ng for HPV-18 (pCGEIB). (B) The inhibition of replication of the 
BPV-1 replication origin is proportional to the amount of introduced p53. The 
replication signals of two independent experiments (72 h posllransfcction) were 
quantified with a Phosphorlmager, and signals from cells transfected with origin 
plasmid only were used as a control to normalize the results. (C) Effect of wt p53 
expression on the transient replication of plasmids containing different BPV-1 
origin constructs in CH04.15 cells. In this assay, 100 ng of wt pS3 expression 
plasmid and 100 ng of each BPV-1 replication origin construct were transfected 
into the cells. Lanes: I and 2, replication of full-length BPV-1 origin plasmid 
pNeoBgl40; 3 and 4, origin plasmid pUCAlu; 5 and 6, origin plasmid pUC12B; 
7 and 8, origin plasmid pUC18A. (D) Schematic representation of the papillo­
mavirus replication origin inserts used. The specific transcription enhancer re­
gion in HPV replication origins (enhancer), the BPV-1 origin A/T-rich region 
(A/T), and El protein (E1BS; unfilled boxes)- and E2 protein (E2BS9, E2BS11, 
and E2BS12; shadowed boxes)-binding sites are indicated. Numbers indicate 
positions on the HPV-11, HPV-18, or BPV-1 nucleotide sequence.
half-life and steady-state level of the p53 protein in cells (19, 
26). All of the mutants except those with point mutation 
Trp248 and deletions ДС305 and Д324-355, gave a specific 
complex with the double-stranded oligonucleotide correspond-
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FIG. 2. Mapping of the p53 domains necessary for suppression of papillo­
mavirus amplificational replication. (A) Schematic representation of p53 mu­
tants. Numbers indicate positions on the amino acid sequence. (B) Southern blot 
analysis of the transient replication of BPV-1 origin plasmid pNcoBgl40 in the 
presence of different p53 mutants in the CH04.15 cell line. Episomal DNA was 
extracted from cclls at 48, 72, and 96 h after transfection and digested with 
restriction endonucleases A /I and Dpn\. Filters were probed with radiolabeled 
HPV-11 URR containing plasmid p7072-99; 100 ng of pNeoBgl40 together with 
250 ng of p53 expression plasmid was transfected into the cells. Lanes 1 to 8 
correspond to the transfections with p53 mutants in the same order as depicted 
in panel A. Carrier, mock-transfected cells; BPV1 ori, control with no added p53. 
(C) Relative inhibition of replication of the BPV-1 replication origin by different 
p53 mutants. The replication signals of three independent experiments (72 h 
posttransfeetion) were quantified with a Phosphorlmager and signals from the 
cells transfected with origin plasmid only were used as a control to normalize the 
results. (D) Southern blot analysis of transient replication of the BPV-1 origin 
plasmid pUCAlu in the presence of additional N-terminal p53 deletion mutants 
in the CH04.15 cell line. Episomal DNA was extracted from cells at 72 and 96 h 
after transfection and digested with restriction endonucleases Art and D pn\. 
Filters were probed with radiolabeled pUCAlu plasmid. Lanes 1,7, 9,10, and 11 
correspond to transfections with p53 mutants as depicted in panel A.
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deletion mutant AN39AC362 all retained the ability to sup­
press replication (Fig. 2B; compare lanes 1, 2, 4, and 7 with 
lane BPV1 ori). The replication signals from three indepen­
dent experiments were measured with a Phosphorlmager, and 
the data are presented in Fig. 2C. The mutants with a deleted 
oligomerization domain (Д324-355) or the whole C-terminal 
part of the protein up to amino acid 305 (ДС305) (Fig. 2B, 
lanes 3 and 5; Fig. 2C) had little or no effect on replication. The 
point mutation Arg248Trp in the DNA-binding domain of the 
p53 protein abolished the suppressor activity of the full-size 
p53 protein (Fig. 2B, lane 6) and even seemed to convert the 
double-deletion mutant AN39AC362 to an activator of repli­
cation (Fig. 2B, lane 8; Fig. 2C). These data indicate that intact 
DNA-binding and oligomerization domains are both necessary 
for the p53 protein activity to suppress papillomavirus DNA 
amplificational replication, while the N-terminal transcription 
activation and С-terminal regulatory domains are dispensable 
for this activity.
The active p53 deletion mutant ДГО9ДС362 contains, in 
addition to the DNA-binding core region (residues 100 to 300), 
flexible linker region (residues 301 to 320), and oligomeriza­
tion domain (residues 320 to 360) (25), also the RPA-binding 
domain (residues 40 to 60) (1, 14, 30) and a proline-rich pu­
tative binding site for proteins with the SH3 domain (residues 
61 to 91) (59). We constructed four additional p53 deletion 
variants and tested their stability and DNA-binding activity. 
The constructed mutants were stable in CH04.15 cells and 
bound DNA sequence specifically, as measured by DNA gel 
shift assay (data not shown). These mutants were used for the 
suppression of replication of the minimal origin plasmid 
pUCAIu in CH04.15 cells (Fig. 2D). None of the newly con­
structed deletion mutants was able to block replication of the 
pUCAIu origin plasmid comparably to wt p53 or AN39AC62. 
These data indicate that four domains of the p53 protein— 
oligomerization (residues 320 to 360), DNA-binding (residues 
100 to 300), proline-rich (residues 61 to 92), and RPA-binding 
(residues 40 to 61) domains—are necessary for the replication 
suppressor activity of the protein.
p53 protein suppresses only amplificational DNA replica­
tion. The action of p53 and its mutants on different replication 
modes was studied in human osteosarcoma cell line 143. The 
143 cell line expresses constitutively EBNA-1, the only viral 
protein necessary for the replication of EBV latent oriP. These 
cells are also permissive for the E l- and E2-dependent repli­
cation of the papillomavirus origin. In contrast to papilloma­
viruses, which quickly amplify their genome after viral entry 
into the cell, EBV oriP probably makes use of the cellular 
control mechanisms that guarantee once-per-cell cycle repli­
cation (65). We cotransfected the plasmids encoding p53 and 
HPV-11 E l and E2 proteins together with the HPV-11 origin 
plasmid and EBV oriP plasmid into the 143 cells and studied 
their replication by Southern blot analysis. The replication 
assay conditions were adjusted so that relative replication sig­
nals of oriP and HPV-11 origin had comparable intensities on 
the same Southern blot. Once-per-cell cycle replication of the 
oriP-containing plasmid was not suppressed by wt p53, while 
amplificational replication of the papillomavirus origin was 
abolished in the same cells (Fig. 3; compare lanes 1 and 2). The 
mutant p53 proteins affected papillomavirus replication simi­
larly in the 143 cells and CHO cells. Mutants AN39 and ДС362, 
which suppressed replication of the BPV-1 full-length origin in 
CH04.15 cells, also blocked replication of the HPV-11 origin 
in the 143 cell line and at the same time had little effect on the 
replication of oriP (lanes 3 and 5). Mutants ДС305 and Д324- 
355 influenced the replication of neither HPV-11 origin nor 
oriP (lanes 4 and 6).
"E EBV oriP + HPV-11 ori
FIG. 3. Southern blot analysis of complication of oriP and HPV-11 origin 
plasmids in human ostcosarcoma 143 cclLs. p53 blocks replication of the papil­
lomavirus origin but not EBV oriP. Episomal DNA was extracted at 48, 72, and 
96 h posttransfeclion, digested with Bum H l and l)p n I, and probed with radio­
labeled origin plasmid p7072-99. One microgram of oriP plasmid p994 and 250 
ng of HPV-11 origin plasmid p7072-99 together with HPV-11 El and E2 expres­
sion plasmids pMT-El and pMT-E2 (1 jjLg of each) were transfected into the 
cells; 250 ng of wt or mutant p53 expression plasmid was added as indicated 
(lanes 2 to 6). Other lanes: oriP and HPV-11 ori, 200 pg of the marker plasmids 
linearized with B am H l; carricr, negative control with carrier DNA only; 1, 
positive emu ml with no added p53.
p53 inhibits amplificational replication of the BPV-1 origin 
in SAOS-2 cells. Replication of the papillomavirus origin was 
tested also in human osteosarcoma SAOS-2 cells that lack 
endogenous p53 and pRB expression. The expression of exog­
enous wt p53 and several transactivation-competent mutants in 
SAOS-2 cells is sufficient to lead the cells to apoptosis (10,68). 
To avoid these side effects, we used p53 mutants deficient in 
transcription activation activity. Cotransfection of the BPV-1 
E l and E2 expression plasmids together with the replication 
origin and p53 expression plasmids into SAOS-2 cells and 
subsequent analysis of the episomal DNA showed that mutants 
AN39 and AN39AC362 inhibited replication of the papilloma­
virus origin in SAOS-2 cells (Fig. 4, lanes 3 and 4), while 
mutants Trp248, AN39AC362 Trp248, and Д324-355 (lanes 2, 
5, and 6, respectively) had no effect on replication. These data 
are similar to the results of experiments with the cell lines 
CH04.15 (using BPV-1 origin) and 143 (using HPV-11 origin) 
and suggest that the suppression of papillomavirus replication 
is a direct intrinsic property of the exogenously expressed p53 
protein and is neither influenced by the endogenous p53 nor 
achieved through the pRB-regulated pathways.
p53 does not cause downregulation of expression of the El 
and E2 proteins. The E l and E2 proteins are absolutely nec-
ДЮ9ДС362
trp248 AN39 ЛЬВ94С362 üp248 Д324-355
FIG. 4. Southern blot analysis of the BPV-1 origin plasmid pUCAIu in 
SAOS-2 cells (radiolabeled origin plasmid pUCAIu used as a pmbe). p53 mutant 
proteins inhibit replication of the BPV-1 minimal origin in SAOS-2 cells lacking 
endogenous p53 and pRB proteins. BPV-1 minimal origin plasmid pUCAIu (500 
ng) together with BPV-1 El and E2 expression plasmids pCGEag and pCGE2 (1 
Hg of each) was transfected into the cells; 500 ng of p53 mutant proteins was 
cotransfected as indicated (lanes 2 to 6). Other lanes: M, 200 pg of the pUCAIu 
marker linearized with /Ч/I; carrier, control transfection with carrier DNA only; 
1, positive control with no p53 construct added.
6X26 L E P IK  E T  A L J . VlROL.
essary for papillomavirus replication. The p53 protein has been 
shown to possess transcription repressor activity in certain 
cases. Theiefore, the inhibition of papillomavirus replication 
could, in principle, be achieved by downregulation of the ex­
pression level or activity of these proteins. We studied the 
expression level and activity of the BPV-1 replication proteins 
in CH04.15 cells in the presence of the overexpressed wt and 
mutant p53 proteins. E2 protein expression is directed by the 
HSP70 promoter, and E l protein expression is directed by the 
SRa promoter in CH04.15 cells (44). These cells are very 
efficiently transfected by electroporation (about 70%, based on 
parallel ß-galactosidase expression vector pC>N260 transfec­
tions), and this fact served as a rationale for the measurements 
described below. The transfected CH04.15 cells were studied 
for the expression level of the E2 protein by Western blot 
analysis of the cell lysates. Transfection efficiencies were de­
termined in parallel in all experiments. Western blot analysis 
did not reveal any reproducible effects of the expression of wt 
or mutant p53 proteins on the steady-state level of the E2 
protein in CH04.15 cells (Fig. 5A). A possibility remained that 
p53 could modulate the activities of the E2 protein, for exam­
ple, the ability to bind DNA.
We performed a DNA mobility shift assay of CH04.15 cell 
lysates transfected with p53 expression constructs. The lysates 
were tested for E2-specific DNA binding with the oligonucle­
otide corresponding to E2-binding site 9 of the BPV-1 genome 
(34). To increase the specificity of the assay, we supershifted 
the E2-DNA complex with an excess of the E2-specific mono­
clonal antibody 3F12. E2-specific radioactive signals were mea­
sured with a Phosphorlmager, and the results were normalized 
to the total amount of protein in the lysate, as determined by 
the Bradford assay (8). As in the case of measuring the steady- 
state level of the E2 protein, we were unable to detect any 
significant changes in the levels of active E2 protein in re­
sponse to the expression of wt or mutant p53 proteins in 
CH04.15 cells (Fig. 5C).
The low expression level of the E l protein in CH04.15 
cells made it impossible to detect E l by quantitative Western 
blot analysis or immunoprecipitation. Instead, we performed 
Northern blot analysis and analyzed the steady-state level of 
the E l mRNA in response to p53 expression (Fig. 5B). The 
transcription level of the E l protein coding sequence was de­
termined relative to ß-actin and ribosomal protein S7 mRNA 
levels on the same blots (Fig. 5B and C), and E l mRNA- 
specific hybridization signals were measured with a Phosphor­
lmager. Quantitation of the E l mRNA level normalized to 
ß-actin and S7 mRNA levels showed no downregulation of the 
E l mRNA level in response to wt and mutant p53 expression 
in CH04.15 cells (Fig. 5C).
These data suggest that the effect of p53 on papillomavirus 
amplificational replication is not caused by downregulation of 
expression of the E l or E2 proteins, although these experi­
ments do not exclude the possibility that p53 interferes with E l 
or E2 (or both) activities at some stage of initiation or elon­
gation of replication.
The inhibition of papillomavirus replication is not the con­
sequence of p53-induced cell cycle block or apoptosis. p53 is a 
mediator of cell cycle block and apoptotic cell death. To ex­
amine the possibility that the suppression of papilloma­
virus amplification is an indirect consequence of any (or both) 
of these effects, we analyzed the p53-transfected CH04.15 cells 
by flow cytometry. Overexpression of wt p53 protein in 
CH04.15 cells induced detectable apoptosis in the culture, as 
shown by the appearance of the sub-G, DNA-containing frac­
tion in the cell cycle profile 48 h posttransfection (Fig. 6A, 
panel 4). To examine the possible connection between p53-
1 2 3 4 5 6 7 8  carrier
FIG. 5. Expression of p53 docs not affect the level of El and E2 expression. 
A p53 expression construct (500 ng) was electroporated into CH04.15 cells. In 
panels 13 and C, lanes and columns 1 to 8 represent transfections with different 
p53 mutants in the same order as in panel A. carrier, control with carrier DNA 
only, CHO, mock-transfected CHO cells (lacking both El and E2 expression). 
All analyses were performed 48 h posltransfeclion. (A) Western blot analysis of 
the E2 protein levels in p53-transfcctcd CH04.15 cells, using a mixture of five 
different E2-spccific monoclonal antibodies (sec Materials and Methods). (B) 
Northern blot analysis of the endogenous El mRNA levels in total RNA prep­
arations from transfected CH04.15 cells. CH0212, total RNA from El-express­
ing cell line CH021Z The same filter was probed first with radiolabeled El - and 
ß-actin-specific probes and then reprobed with ribosomal protein S7-spccific 
probe. Approximate lengths for mRNAs are 700 bp for S7, 2.0 kb for ß-actin and 
2.3 kb for El. (C) Quantitation of the El Northern blots and E2 gel shift assay 
with a Phosphorlmager. The El mRNA-specific signals in the total RNA prep­
arations were normalized to the ß-actin (open columns) and ribosomal protein 
S7 (shaded columns) mRNA signals in the RNA samples. Black columns rep­
resent the E2 gel shift data. The E2-spccific signal in the lysates of the mock- 
transfected cells and the normalized El mRNA-specific signal from carrier- 
transfected control cells were set at 1.0 in each experimental series. Each column 
represents the average of two independent experiments.
induced apoptosis and the suppression of replication, we made 
use of the ability of the Bcl2 protein to prevent the p53- 
induced apoptosis of cells (51). Increasing amounts of the BcI2 
expression plasmid were transfected into the cells. The expres­
sion of BcI2 considerably reduced the amount of cells in the 
sub-G, DNA-containing fraction of the cells transfected with 
wt p53 (compare panels 4, 5, and 6). The cells transfected with 
p53 deletion mutant ДЮ9ДС362 as well as with the same 
deletion mutant with the Arg248Trp point mutation had some 
small sub-G, fraction, probably induced by electroporation, 
which was not influenced by the expression of Bcl2 in the cells 
(panels 7 to 12). The percentage of the apoptotic cells in these 
experiments was measured also by the TUNEL assay (Table 
1), which gave essentially the same result and showed that Bcl2 
expression in CH04.15 cells reduced considerably the number 
of the p53-induced apoptotic cells in the culture. The distribu­
tion of CH04.15 cells in G,/G„, S, and G2/M stages of the cell
14
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without BCL2
G0/Gl-<n.2
S-24.2
G2/M-14.6
subGl
2.6
subGl
2.3
GO/G1-58.3
S-24.3
G2/M-17.5
GO/G1-61.8
S-23.6
G2/M-14.6
subGl
2.7
GO/G1-58.9
S-27.9
G2/M-13.2
subGl
6.2
GO/G 1-63.2
S-23.6
G2/M-13.2
subGl
7.2
Gl-61.0
S-25.7
G2/M-13.3
subGl
15.2
G0/GI-60.9
S-25.9
G2/M-13.2
subGl
6.1
GO/G1-63.1
S-23.7
G2/M-13.2
subGl
5.7
G0/G1-59.3
S-25.0
G2/M-15.7
subGl
4.4
GO/G1-59.7
S-23.6
G2/M-16.7
G0/G1-61.1
S-24.6
G2/M-14.3
subGl
3.7
subGl
4.8
G0/G1-58.4
S-24.9
G2/M-I6.7
subGl
2.4
FIG. 6. Suppression of BPV-1 amplificational replication by p53 proteins is not the consequence of the p53-induced apoptosis or cell cycle block. (A) Flow 
cytometric analysis of the ccll cycle distribution and the sub-G, DNA-containing apoptotic fraction of the p53-transfected CH04.15 cells. In this assay, 250 ng of the 
p53 expression constructs without Bcl2 or together with 1(K) or 250 ng of the Bcl2 expression plasmid pcDBCL2 was transfected into the CH04.15 cells; 100 ng of BPV-1 
full-length origin plasmid pNeoBg!40 was used in each transfection, control, cells with no p53 expression constructs added. Cells were fixed 48 h after transfection. The 
percentage of apoptotic sub-G, DNA-containing signals and the calculated percentages of cells in G,/G,, S, ami GVM phases (from total of 50,000 cells) are indicated 
on the each graph. у  axis, cell number; x  axis, DNA content. The sub-G, DNA fraction was not considered in the cell cycle calculations. Standard software provided 
by the manufacturer (Odam-Brucker) was used for the cell cycle calculations. (B) Southern blot analysis of the episomal DNA in the cells cotransfected with p53, Bcl2, 
and the BPV-1 origin plasmid pNeoBgl40. Episomal DNA was extracted at 72 and 96 h after transfection, digested with //m dlll and D pn\, and probed with radiolabeled 
origin plasmid pUCAIu. Lanes: M, 200 pg of the marker plasmid linearized with W/mllll; 1 to 12, transfections 1 to 12 in panel A.
cycle was not influenced by the expression of Bc!2 or p53. We 
also analyzed if the Bcl2 rescues the replication suppression 
induced by p53 or its mutants. Expression of Bcl2 in CH04.15 
cells did not influence the replication of the BPV-1 origin 
itself, nor did it abrogate the inhibitory effects of wt p53 and 
deletion mutant AN39AC362 on replication of the origin (Fig.
6B, lanes 1 to 9). These data support the conclusion that the 
effect of the p53 protein on papillomavirus amplificational 
replication is not an indirect consequence of cell cycle block or 
apoptotic cell death.
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TA B LE i. A pop to tic  fraction  in to ta l popu lation  o f C H 0 4 .15 
cells transfected  with p53 and  Bcl2 constructs 
(as m easured  by T U N E L  assay)
Cells
Apoptotic fraction (%)
No Bcl2 
cotransfected
250 ng of Bcl2 
cotransfected
Control (no p53 transfected) ND" 2.9
Transfected with p53 construct:
wt p53 19.2 6.0
ДГО9ДС362 2.3 6.7
ДЮ 9ДС362Тгр248 4.8 N D
" ND, mil determined.
DISCUSSION
p53 as a suppressor of papillomavirus amplificational rep­
lication: possible implications for virus-cell interactions. Am­
plificational replication of papillomavirus DNA is initiated af­
ter entry of the viral genome into the cell nucleus, which leads 
to a rapid increase in copy number of the virus genome during 
S phase (20). Papillomaviruses rely on cellular replication fac­
tors and enzymes (40) and coordinate the initiation of repli­
cation by two viral origin recognition and initiation proteins, 
E l and E2 (11,45,56, 57,64). The same viral proteins are used 
at the following latent replication stage. The mechanism of 
switching from amplificational to controlled-maintenance rep­
lication is unknown. Our data show that amplificational repli­
cation of bovine and different human papillomaviruses in the 
short-term replication assay can be suppressed by the p53 
protein in all cell lines studied. It seems not to require any 
response elements in the origin of replication. It also does not 
require any activities carried by the С-terminal regulatory and 
N-terminal transactivation domains of the p53 protein, includ­
ing the ability to activate transcription. The DNA-binding do­
main of p53 has been shown to be the target for most of the 
missense mutations which inactivate the tumor suppressor 
function of this protein in cells (12). Incidentally, the very same 
mutations inactivated p53 in the replication system studied.
p53 has been shown to block the replication of SV40 by 
interacting with large T antigen. The binding of SV40 large T 
antigen by the p53 protein downregulates the helicase function 
of the T antigen (52); in addition, p53 competes with DNA 
polymerase a  for the binding of SV40 large T antigen at the 
initiation of SV40 DNA synthesis (16). Mouse polyomavirus 
replication was shown not to be inhibited by the p53 protein 
(22, 39) unless additional (up to 16) p53-specific RGC sites 
were included in the plasmid (39). This shows that sensitivity of 
the viruses within the papovavirus family to the action of tumor 
suppressor protein p53 is variable and obviously reflects the 
differences in the viral life cycles and different strategies for the 
utilization of cellular control mechanisms by these viruses. 
Papillomaviruses must infect basal epithelial cells in order to 
establish productive infection of basal and suprabasal epithe­
lial cells. Amplificational replication of the viral genome in 
these cells is essential for the establishment of infection. Tlie 
oncoproteins encoded by the E5, E6, and E7 open reading 
frames of papillomaviruses are essential for providing the cel­
lular environment for the replication of viral DNA. However, 
amplificational replication has to be controlled in order to 
avoid overreplication and unscheduled death of basal or su­
prabasal cells, because the synthesis of late genes and the 
production of infectious particles takes place only in the ter­
minally differentiated epithelial cells. It is tempting to specu­
late that the ability of p53 to block the papillomavirus ampli­
ficational replication characterized in the model system studied 
is actually used by the virus to control the productive infection 
of basal cells. The E6 proteins of the high-risk (50) and low- 
risk (35) HPVs have been shown to interact with p53; however, 
only E6 from the high-risk HPVs directs p53 to degradation 
(50). It can be speculated that the binding of p53 by the E6 
proteins of either high-risk or low-risk human and animal vi­
ruses reduces the replication suppressor activity of p53. Other 
important players in this regulatory mechanism are the repli­
cation proteins E l and E2, which determine the efficiency of 
initiation of replication. The expression level of these proteins 
would certainly depend on the copy number of the viral ge­
nome, therefore providing the positive feedback for amplifica­
tion. The papillomavirus replication proteins E l and/or E2 
have been shown to repress the promoter which is closest to 
the replication origin and directs E6 expression (31, 38,49, 58). 
Therefore, higher levels of the E l and E2 proteins would 
reduce the level of E6, which in turn results in the higher level 
of the active p53 protein capable of suppressing replication. 
These interrelationships among p53, E6, E l, and/or E2 pro­
teins could provide a regulatory loop which can be used by 
some papillomaviruses to keep viral genome amplification in 
optimal limits (Fig. 7). The proposed regulatory loop could 
further serve as one of the mechanisms for the copy number 
control of the replication of papillomavirus genome during the 
latent infection of the basal cells. However, the mechanism 
may be different with different papillomavirus types, as, for 
example, attempts to find any interaction between BPV-1 E6 
and p53 have appeared to be unsuccessful. It is still possible 
that in this case some other step in the cellular control path­
ways, up- or downstream of p53 itself, may be neutralized by 
viral regulatory proteins.
The putative mechanism of action of the p53 protein. The 
p53 protein, in principle, could suppress papillomavirus DNA 
replication in vivo by a number of different mechanisms, such 
as by arresting the cell cycle, inducing apoptotic death of cells, 
downregulating the expression or activity of the E l and E2 
proteins, or interfering with viral and cellular replication pro­
teins at the stages of initiation or elongation of DNA replica­
tion.
The induction of apoptosis or cell cycle block is an unlikely 
mechanism for the apparent suppression of replication by p53 
or its mutants in the cells studied, as shown by the nieasure-
FIG. 7. A putative p53-conlrolletl regulatory loop in the amplificational rep­
lication step of the papillomavirus life cycle.
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ment of apoptosis and distribution of cells in the cell cycle. In 
addition, the efficient rescue of CH04.15 cells from the wt 
p53-induced apoptosis by Bcl2 expression did not affect the 
suppression of BPV-1 origin replication in the same cells. Mu­
tant AN39AC362 efficiently blocked replication of the papillo­
mavirus origin in all of the studied cells but was unable to 
induce any detectable apoptosis. Additional convincing data 
come from the coreplication assay of the EBV and HPV-11 
origins, which show that in the same cells two origins have 
differing sensitivity to the expression of p53 or its mutants. 
Replication of EBV oriP (65) and the papillomavirus origin 
(18) takes places during the S phase of the cell cycle, and 
intensive apoptotic death of the cells or cell cycle block should 
have also considerably reduced the replication of EBV oriP. 
Therefore, these experiments exclude several indirect and ob­
vious explanations for the observed suppression of papilloma­
virus amplificational replication. It also seems unlikely in the 
light of these data that the replication block could have been 
achieved through the inactivation of general replication factors 
such as RPA, PCNA, and others by the expression of p53 or its 
mutants, because those factors are presumably used for the 
replication of EBV oriP and chromosomal DNA as well.
Another simple explanation is that the p53-induced suppres­
sion of papillomavirus replication could have been achieved 
through negatively modulating the activity of essential viral 
replication proteins (similarly to the case of SV40 virus) or 
through downregulating the expression of these proteins. How­
ever, we could not detect any significant p53-induced drop of 
the expression level and DNA-binding activity of the E2 pro­
tein and transcription level of E l in CH04.15 cells. Also, there 
are no data in the literature showing the interaction of the p53 
protein with the E l or E2 proteins of any papillomaviruses or 
demonstrating the modulation of activities of these proteins by 
p53. Therefore, the p53 protein has to act at later stages of 
replication initiation process, i.e., loading of the replication 
complex on the origin, unwinding of DNA, or elongation of the 
replication fork.
Our findings are substantiated by the fact that the C-tenmi- 
nally truncated form of the p53 protein (analogous to our 
mutant ДС362) is able to block nuclear DNA replication in 
vitro in the transcription-free DNA replication extract from 
Xcnopus lacvis activated eggs (13). As for the suppression of 
amplificational replication of papillomavirus origin in the so­
matic cells, the DNA-binding activity of p53 was needed for the 
block of nuclear DNA replication in the transcription-free 
Xcnopus extracts. It is possible that these two replication sys­
tems have similar p53-sensitive steps. Mapping of the p53 
protein domains necessary for the repression of papillomavirus 
amplificational replication demonstrated that the intact DNA- 
binding core and oligomerization domains are clearly neces­
sary. Several activities have been mapped to the core domain, 
including the sequence-specific DNA-binding (6, 43, 61), 
ssDNA-binding (4), and 3'-to-5' exonuclease (41) activities of 
the p53 protein. All these activities, as well as the ability to 
suppress papillomavirus amplificational replication, are inacti­
vated by point mutations which either abolish the direct con­
tact of the protein with DNA or induce inactive conformation 
of the protein (12, 41). It is unlikely that the sequence-specific 
double-stranded DNA-binding function of p53 could be re­
sponsible for the suppression of amplificational replication, 
while sequence-nonspecific ssDNA-binding activity could be 
used by the p53 protein in this process.
Full-length p53 protein DNA-binding activity is regulated, 
sterically or allosterically, by the С-terminal domain of the 
protein (for a review, see reference 25). In addition, the C- 
terminal domain binds to DNA bulges resulting from DNA
deletion/insertion mismatches (29) and also to the ends of 
short ssDNA molecules (5), promoting the reannealing of 
complementary strands (9,42). Deletion of the last 30 residues, 
which has previously been shown to remove the above-men­
tioned activities of the p53 protein, did not affect its ability to 
suppress papillomavirus amplification in our assays. However, 
it is possible that both the ssDNA-binding and reannealing 
functions of the С terminus additionally contribute to the am­
plification suppressor activity of p53 in the case of the full- 
length protein.
Core and oligomerization domains, though necessary, are 
not sufficient for the replication suppressor activity. An addi­
tional N-terminal sequence that has been shown to contain two 
intriguing determinants, RPA-binding (residues 40 to 60) and 
proline-rich (residues 61 to 90) domains, is also needed. De­
letion of any or both of these domains crippled the p53 protein 
in the replication suppression assay. It is highly likely that p53 
coordinates its replication suppressor activity with other pro­
teins bound on the ssDNA, such as through the interaction 
with RPA (14). RPA facilitates DNA unwinding and DNA 
synthesis in the initiation and elongation stages of DNA rep­
lication (63). The interaction of p53 with RPA could be im­
portant in two respects. First, ssDNA-bound RPA could be the 
target for p53 action, and its interaction with p53 could seques­
ter RPA from the ssDNA; second, interaction between RPA 
and p53 on the stabilized ssDNA facilitates recognition of the 
amplifying DNA by p53. Interaction of p53 and RPA in solu­
tion does not require an intact DNA-binding domain (1, 14, 
30), while it is needed for the suppression of replication. This 
suggests the possibility that p53-RPA interaction takes place 
on the ssDNA. Deletion mapping of p53 activity showed that 
also the proline-rich putative signalling domain in the N-ter- 
minal part of the protein is required for the suppression of 
papillomavirus replication. This domain contains several cop­
ies of the PXXP motif (P represents proline; X represents any 
amino acid), which constitute a binding site for the proteins 
with the SH3 domain (59). It has been suggested that this 
domain plays a critical role in the transmission of transactiva­
tion-independent antiproliferative signals and presumably 
links p53 directly to the appropriate signal transduction path­
ways (46, 59).
However, despite the findings provided here pointing to an 
attractive putative mechanism, additional experimental data 
are needed to determine in detail the mechanism of action of 
p53 in the suppression of papillomavirus amplificational repli­
cation.
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Papillomavirus genomes are stably maintained as extrachromosomal nuclear plasmids in dividing host cells. 
To address the mechanisms responsible for stable maintenance of virus, we examined nuclear compartmen- 
talization of plasmids containing the full-length upstream regulatory region (URR) from the bovine papillo­
mavirus type 1 (BPV1) genome. We found that these plasmids are tightly associated with the nuclear chromatin 
both in the stable cell lines that maintain episomal copies of the plasmids and in transiently transfected cells 
expressing the viral El and E2 proteins. Further analysis of viral factors revealed that the E2 protein in Irans 
and its multiple binding sites in cis are both necessary and sufficient for the chromatin attachment of the 
plasmids. On the other hand, the BPV1 URR-dependent plasmid replication and chromatin attachment 
processes are clearly independent of each other. The ability of the plasmids to stably maintain episomes 
correlates clearly with their chromatin association function. These data suggest that viral E2 protein-mediated 
attachment of BPV1 genomes to the host cell chromatin could provide a mechanism for the coupling of viral 
genome multiplication and partitioning to the host cell cycle during viral latent infection.
Precise maintenance of the cellular genome requires exact 
doubling of the genome once and only once during the S phase 
and proper partitioning of the chromosomes between the daugh­
ter cells during the M phase of the cell cycle (26). Some DNA 
viruses, like papillomaviruses and Epstein-Barr virus (EBV), rep­
licate as episomal multicopy nuclear plasmids in the host cells’ 
nuclei during a latent infection (11,13). In order to be successfully 
maintained in host cells during latency, these viruses have to pos­
sess certain control mechanisms that couple multiplication of the 
viral genome and partitioning to the host genome maintenance 
cycle. The relatively small size of the papillomavirus genome 
puts certain limits on the use of these maintenance mechanisms. 
It is clear, for example, that episomal DNA viruses, unlike the 
cellular chromosomes, cannot afford to possess long and complex 
centromeric regions in their genomes that could ensure the 
proper partitioning and nuclear retention functions during mi­
tosis. Therefore, some other strategy has to be used instead.
Papillomaviruses infect basal epithelial and mucosal cells in 
a wide range of different hosts. The infection can cause benign 
or malignant lesions; the most known example is common skin 
warts. Papillomavirus genome replication can be generally de­
scribed as a three-step process (11). After entry into the basal 
cells, the viral genomes are quickly amplified in the host cell 
nucleus. Initial amplification is followed by a viral latency pe­
riod, during which the viral genomes are maintained extra- 
chromosomally at a constant copy number in the proliferating 
host cells. The final, vegetative amplification stage, where the for­
mation of new infectious particles occurs, takes place only after 
the host cells have terminally differentiated into keratinocytes.
The process of initiation of papillomavirus DNA replication
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has been extensively studied, focusing mainly on bovine pap­
illomavirus type 1 (BPV1) as a model. Only two viral pro­
teins—E l and E2—are required for this process, and all other 
necessary components are derived from the host replication 
machinery (5, 16, 38-40). E l has been shown to be a viral 
origin recognition factor and helicase (12, 33, 41). E2, apart 
from being a central viral transcription regulator (9, 23), also 
acts as an auxiliary factor that binds to E l and to the replica­
tion origin in a cooperative manner, thus facilitating the for­
mation of replication initiation complex (2, 21, 24, 32, 35). The 
origin of papillomavirus replication has been located to the 
noncoding upstream regulatory region (URR). The minimal 
part of the URR, sufficient for the initiation of viral replication 
(minimal origin of replication), is composed of an A/T-rich 
region, binding site for E l, and one binding site for E2 (37,39). 
URR sequences of different papillomaviruses contain a differ­
ent number of E2 binding sites that also play an important role 
in viral latency. The URR of BPV1 contains 12 E2 binding 
sites that together form a BPV1 minichromosome mainte­
nance element (MME). This element, in addition to the min­
imal origin of replication, is required for long-term episomal 
maintenance of BPV1 replicator in cells expressing the E l and 
E2 proteins. A sufficient number of high-affinity E2 binding 
sites is critical for proper MME function (27). However, the 
function of E2 binding sites in the stable maintenance of the 
viral genome has been unclear until lately. Two recent publi­
cations provided the first insights, showing that BPV1 genomes, 
as well as E2 protein, are localized to host cell mitotic chro­
matin in C127 mouse fibroblasts and that mutations in E2 and 
E l coding regions are able to affect such localization (18, 34).
In this study, we demonstrate that MME is likely to exert its 
role in episomal minichromosome maintenance of the BPV1 
genome through the viral E2 protein-mediated association 
with the host cell nuclear chromatin. Viral E2 protein in Irans 
and MME, comprised of multiple E2 binding sites, in cis, are
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both necessary and sufficient for chromatin attachment of the 
plasmids in our model system. On the other hand, the E l 
protein or its binding site as well as the plasmid replication 
function can be removed without affecting the plasmid associ­
ation with the chromatin. These data suggest that E2-mediated 
association of the viral genomes with nuclear chromatin is 
likely to guarantee the proper partitioning and nuclear reten­
tion of papillomavirus genomes in dividing cells as well as the 
optimal exposure of papillomavirus replicon to cellular repli­
cation control mechanisms during S phase. Therefore, the 
BPV1 stable episomal maintenance consists of two main func­
tions—chromatin attachment, which provides proper partition­
ing and nuclear retention to the viral genomes, and replication 
function, which is responsible for compensation of the plasmid 
loss during host cell division.
MATERIALS AND METHODS
Plasmid constructs. Plasmid pNeolOE2BS9 contains 10 oligomerized head- 
to-tail copies of high-affinity E2 binding site 9 and was constructed by inserting 
the B a m H l-E cllib ll fragment (containing the synthetic E2 binding site oli­
gomer) from plasmid Msp/15+10xBS9 (37) between BamHX and H pal sites of 
pNeo vector. All other BPVI URR plasmids (27) and BPV-1 El expression 
vector pCGEag (38) were described previously.
Cells and transfections. Chinese hamster ovary cell line (CHO) derivatives 
CH049 (expressing BPV1 E2 protein), CH04.15 (expressing BPV1 E l and E2), 
and CHOBgMO (CH04.15 cells that maintain BPV-1 full-length URU plasmid 
pNeoBgl40 episomally) (27) were maintained in Ham’s F12 medium supple­
mented with 10% fetal calf serum. Electroporation experiments were performed 
with a Bio-Rad Gene Pulser with capacitance and voltage settings of 975 (il7 and 
230 V, respectively. The transfection efficiencies were determined by in situ 
staining of the cells transfected in parallel with a ß-galaetosidase-expressing 
plasmid pON260 (38). file extraction of episomal DNA from cells and its 
analysis by Southern blotting were performed as described previously (38).
Cytogenetic analysis. Chromosome preparations were done bv standard meth­
ods. Briefly, cells were exposed to Colcemid added at a final concentration of 0.1 
|j.g/ml for 1 to 4 h to enrich the mitotic fraction. Colcemid-treated cells were 
harvested by trypsin treatment and suspended in a 0.075 M KC1 solution, incu­
bated at room temperature for 15 min, and fixed in ice-cold methanol-glacial 
acetic acid (3:1 [vol/vol]). The spread-out chromosomes at metaphase and nuclei 
at interphase for cytogenetic or fluorescence in situ hybridization analysis were 
prepared by dropping the cell suspension on wet slides. Chromosome analysis 
was performed by standard staining methods. CHO cells were karyotyped by 
G-banding analysis as described previously (4).
FISH. Cells were harvested and prepared for analysis as described above. 
Hybridization probes were generated by nick translation, using biotin-16-dUTP 
as a label and pNeoBgWO plasmid as a template. The final size of probe frag­
ments was adjusted to 100 to 300 bp by DNase I digestion in all cases. Fluores­
cence in situ hybridization (FISH) was performed essentially by the protocol of 
Tucker and coauthors (36). Briefly, chromosome preparations were denatured al 
70°C in 70% formamide (pH 7.0 to 7.3) for 5 min, then immediately dehydrated 
in a series of washes (70,85, and 96% ice-cold ethanol washes [for 3 min each]), 
and air dried. The hybridization mixture (18 ц.1 per slide) was composed of 50% 
formamide in 2X SSC (IX SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 
10% dextran sulfate, 160 ng of a biotinylated plasmid probe DNA, and 10 м-g of 
herring sperm carrier DNA After 5 min of denaturation at 70°C, probe DNA 
was applied to each slide, sealed under a eoverslip, and hybridized for 2 days at 
37°С in a moist chamber. The slides were washed in three changes of 2x  SSC 
containing 50% formamide, 2x SSC, and 2x SSC containing 0.1% IGEPAL 
CA-630 (Sigma Chemical Co.) at 45°C. Prior to immunofluorescence detection, 
slides were preincubated for 5 min in PNM buffer (PN buffer [25.2 g Na->HPOj • 
711,0,0.83 g NaII2P04 • 11,0, and 0.6 ml of IGEPAL CA-630 in 1 liter õf R.O] 
with 5% nonfat dried milk and 0.02% sodium azide). After that, the probe was 
detected with fluorescein isothiocyanate (FITC)-conjugated extravidin. The sig­
nal was amplified with biotinylated antiavidin antibody and a second round of 
extravidin-FITC treatment. Between each of the steps, the slides were washed in 
PN buffer containing 0.05% IGEPAL CA-630 at room temperature for 15 min. 
Chromosomes were counterstained with propidium iodide and mounted in p- 
phenylenediamine antifade mounting medium. Slides were analyzed with a 
Olympos VANOX-S fluorescence microscope equipped with appropriate filter 
set. All FISH experiments were coded, and the chromosomes from at least 50 
cells at metaphase and at least 200 interphase nuclei were analyzed on each slide. 
In addition, two slides from each sample were prepared, hybridized, and scored 
on different dates. Fuji Fujicolor and Agfa Agfacolor films for color prints were 
used for photomicrographs.
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FIG. 1. Schematic representation and some relevant properties of the BPVI 
URR constructs used in this study. The presence (+) or absence ( - )  of intact 
replication origin (replication), intact MME (sufficient number of E2 binding 
sites), competence for stable episomal maintenance in the long-term assay (sta­
ble maintenance), and competence of the construct for attachment to the host 
cell chromatin as determined by FISH analysis are indicated to the left of the 
schematic representations. The numbers in the schematically represented DNA 
sequences are the nucleotide positions in the BPVI genome.
RESULTS
BPVI URR-containing plasmids are associated with the 
host cell chromatin. It has been shown that the full-length 
BPVI genomes are attached to the chromatin in C127 cells 
(18, 34). First we decided to examine whether the plasmids, 
which contain only the BPVI URR sequences, possess the 
same ability in the Chinese hamster ovary (CHO) cell line- 
based model system, developed by us for the study of transient 
replication and stable maintenance of BPVI (27, 39). We first 
analyzed the CHOBgWO cell line, which expresses the BPVI 
E l and E2 proteins from integrated cassettes and maintains 
extrachromosomally the full-length BPVI URR (Fig. 1) con­
taining plasmid pNeoBgl40. A FISH analysis of both, prefixed 
mitotic metaphase spreads and interphase nuclei was per­
formed with biotin-labelled BPVI URR plasmid-specific DNA 
probe. The signals from hybridized probe were detected and 
amplified with FITC-conjugated extravidin and antiavidin an­
tibodies, as described in Materials and Methods. The repre­
sentative data are shown in Fig. 2A. The discrete yellow 
dots corresponding to plasmid-specific signals appeared as a 
merged yellow signal of the green FITC fluorescence on the 
red background of nuclear DNA stained with propidium io­
dide. The BPVI URR plasmid signals were localized on the 
metaphase chromosomes with obviously random pattern dis­
tribution. Random distribution of plasmid signals was also 
observed in the interphase nuclei. Almost all (—90%) inter­
phase nuclei and mitotic metaphase chromosomes from 180 
analyzed cells contained BPVI URR plasmid-specific signals, 
with overall number of plasmid signals from around 10 to 50 
per nucleus in the majority of individual nuclei analyzed. This 
number is close to the estimated average of episomal plasmid 
copy number in CHOBgMO cells (27), suggesting that FISH 
analysis was sensitive enough to detect every single plasmid 
copy in fixed nuclei. A small proportion of the cells from the 
total population contained higher number of signals (2% of 
cells containing more than 40 signals). However, the fractions 
of both high-copy-number and plasmid-negative phenotype 
nuclei varied significantly (up to 20% in both fractions) in 
several other CHOBgWO subclones that were derived from the 
same long-term passage cell population. This apparent heter­
ogeneity supports the earlier suggestion based on the similar 
phenotype in the case of long-term stable maintenance of
Xho-Hpa i. 
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full-length BPV1 genomes (28, 29, 31), that the papillomavirus 
partitioning and replication processes are not subjected to very 
strict control mechanisms.
In addition to plasmid-specific randomly distributed single 
dots, two hybridization signals represented by double dots, one 
on both sister chromatids, were present on the spread-out 
chromosomes of CHOBgMO cells. More-prominent hybridiza­
tion signal on marker chromosome 8 (mar8) and much weaker 
signal on marker chromosome 4 (mar4) correspond to the ge­
nome-integrated E l and E2 expression cassettes and appear as 
a result of cross-hybridization between bacterial plasmid back­
bones of the probe DNA and integrated expression cassettes. 
The same integrated markers were also present in the case of 
cell line CH04.15, which is the BPV1 E l- and E2-expressing 
parental cell line used to generate the CHOBgWO cells.
After verifying the attachment of stably maintained BPV1 
URR plasmid to host mitotic chromatin, we next decided to 
examine whether similar attachment occurs in the case of tran- 
sient-replication assay with the same plasmid. For this exper­
iment, the BPV1 E l- and E2-expressing cell line CH04.15 was 
transfected with plasmid pNeoBgl40, which contains the full- 
length URR of BPV1, cells were fixed 48 h after transfection, 
and the plasmid localization in interphase nuclei and on meta- 
phase chromosomes was determined by FISH. Similar to the 
results obtained with stably maintained plasmid, randomly dis­
tributed BPVI URR-plasmid specific signals were observed both 
on metaphase chromosomes and in interphase nuclei (Fig. 2B).
We conclude from these data that the BPV1 URR-contain- 
ing plasmids are able to associate with host chromatin in the 
BPV1 E l and E2 protein-expressing cells. The association with 
host chromatin is not dependent on the URR plasmid status, 
appearing both in the case of stably maintained and transiently 
replicating plasmid.
The multimerized E2 protein binding sites determine the 
chromatin attachment of the plasmids in the CH04.15 cells. 
The data presented above showed clearly that chromatin at­
tachment of the BPV1 URR plasmids could be studied in 
transient-transfection assay. A panel of different BPV1 URR- 
derived constructs (Fig. 1) in the same plasmid context, 
pNeo5', was transfected into the BPV1 E l- and E2-expressing 
cell line CH04.15. Half of the cells were fixed after 48 h, and 
FISH analysis of the plasmid localization with specific DNA 
probe was performed. Low-molecular-weight DNA was ex­
tracted from the other half of the cells and analyzed by South­
ern blotting to estimate the overall level and replication com­
petence of the transfected plasmid DNA in cells. FISH analysis 
indicated that in addition to the intact full-length URR plas­
mid (Bgl40) (Fig. 2B), the plasmid containing URR with dis­
rupted E l binding site (Xho—>Hpa) also displays the localiza­
tion to mitotic chromatin (Fig. 2C). The fraction of nuclei 
considered plasmid positive was smaller (usually 10 to 20%) 
than the transfection efficiencies estimated in parallel with 
ß-galactosidase expression plasmids (60 to 70%). These differ­
ences may be explained by different sensitivities of ß-galacto- 
sidase staining and FISH protocols. Alternatively, the lower 
percentage of the positive cells by FISH analysis may indicate 
that not all plasmid molecules that reach the nucleus after 
transfection will be able to attach to the chromatin or perhaps 
they will require longer incubation periods. For example, the
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FIG. 3. Southern blot analysis of the exlrachromosomal DNA from cells used 
for the parallel FISH analysis (sec Fig. 2 for FISH results). Lane M contains 1(M 
pg of linearized plasmid marker (pNeoBgMO). Lancs 1 and 2 contain extraehro- 
mosomal DNA from CHC)Bgl40 cells maintaining the I3PV1 URR plasmid 
pNeoBgl40 cpisomally, and all the other lanes correspond to different Iransfec- 
tioas with BPV1 URR constructs (1 (jug of each plasmid) in CH04.15 cells. The 
mock-transfected control cells (carrier) are indicated. DNA preparations were 
digested with the appropriate restriction enzyme to linearize the plasmid DNA 
and with D pnI where indicated (+  if added, — if not) which digests only bacte- 
rially methylated DNA thus revealing the dc novo-rcplicatcd plasmid pool.
successful establishment of the chromatin association may be 
dependent on passage of the cells through the particular cell 
cycle phase. One possible explanation could also be that chro­
matin attachment requires higher E2 levels than in some of the 
cells, but previous immunofluorescence analysis of the status of 
the E2 protein has not revealed any significant heterogeneity in 
the used subclones of CH04.15 cell line (data not shown).
Plasmids with no BPVI URR sequences (Fig. 2G) or con­
taining essentially the minimal replication origin (Fig. 2D) with 
two E2 binding sites failed to give any plasmid retention in the 
interphase nuclei and on the metaphase chromosomes. On the 
other hand, parallel Southern blots indicated that the plasmid 
DNA was present in these cells at levels comparable to those 
detected in the case of plasmids that were able to localize to 
mitotic chromosomes (Fig. 3). For reasons that are not clear at 
this time, the vector molecule constantly gave lower signals 
upon harvesting in the transfected cells under the same trans­
fection conditions (compare lane 13 with the other lanes with 
other input plasmids [Fig. 3]). Dpnl cleavage also demonstrat­
ed that minimal replication origin-containing plasmid pUCAlu, 
despite failing to associate with mitotic chromatin, at the same 
time replicated efficiently in transfected cells. These data sug­
gest the possibility that BPV1 origin-dependent replication 
may take place both in the chromatin-associated form, as in the 
case of URR-containing plasmids, and freely in the nucle­
oplasm, as in the case of minimal replication origin plasmid 
pUCAlu. The presence of СН04.15 cell line-specific cross- 
hybridization signals on marker chromosomes mar4 and mar8 
(see above) served as an additional internal control verifying 
the success of the FISH procedure.
We conclude from these data that the chromosomal locali­
zation of plasmid-specific hybridization signals in the case of cer­
tain BPV1 URR constructs is not an indication of some unspe­
cific feature of plasmid DNA but rather reflects the association 
with host mitotic chromatin that is dependent specifically on 
BPV1 URR sequences. Plasmids that are not bound to the 
chromatin are washed away from both the chromosome com­
plexes at metaphase and the nuclei at interphase during fixa­
tion and hybridization procedures, as the lack of plasmid signal
FIG. 2. Multiple E2 binding sites determine the competence for chromatin attachment, but a functional replication origin is not necessary for this activity. The 
results of FISH analysis in the CHOBgWO cell line that stably maintains a full-length BPV1 URR plasmid pNcoBgl4<) (A) and of CH04.15 cells transfected with 
plasmids (1 ng) containing different BPV1 URR inserts (B to G) that are depicted schematically in Fig. 1. Panel G shows the control experiment with plasmid containing 
no URR sequences El and E2 expression cassettes integrated into genome give cross-hybridization signals represented by double dots (indicated by arrowheads).
FIG. 4. The chromatin attachment of URR plasmids occurs also in the absence of El expression; E2 protein determines the attachment activity. The results of FISH 
analysis in the transient assay using cell line CTI049 that expresses only BPVi E2 protein are shown. Cells were transfected with 1 p.g of plasmids containing BPV1 URR inserts 
depicted schematically in Fig. 1. E2 expression cassette integrated into genome gives cross-hybridization signal represented by double dots (indicated by arrowheads).
on metaphase chromosomes was always accompanied by the 
lack or very low percentage of signals in the interphase nuclei.
The failure of replicating BPV1 URR deletion construcM/u 
to attach to the mitotic chromosomes leads us to the conclu­
sion that replication and chromatin attachment are separate 
properties of the BPV1 replicon. This conclusion is farther 
supported by the localization of the replication-deficient con­
struct Xho—>Hpa to mitotic chromatin (Fig. 2C). On the other 
hand, the attachment of plasmids to chromatin was dependent 
on the presence of a sufficient number of high-affinity E2 bind­
ing sites in cis. As shown above, BPV1 URR constructs with 
intact set of 12 E2 binding sites (Bgl40 and Xho—>Hpa) were 
able to attach to chromatin. The addition of 10 oligomerized 
high-affinity binding sites was able to restore the chromosome 
attachment activity to the construct with only two E2 binding 
sites (Fig. 2E). Moreover, FISH analysis demonstrated that 
insertion of 10 oligomerized high-affinity E2 binding sites alone 
into the vector was sufficient to provide the chromatin attach­
ment activity to plasmid DNA in the absence of any other 
additional BPV1 URR sequences (Fig. 2F). We conclude from 
these data thaL a sufficient number of high-affinity E2 binding 
sites determines the plasmid association to chromosomes.
Multiple E2 binding sites in cis and viral E2 protein in Irans 
are the viral determinants of the chromatin attachment activ­
ity of the BPV1 URR-derived plasmids. The fact that oligomer­
ized E2 binding sites were sufficient while functional repli­
cation origin and replication ability were unnecessary for 
chromatin attachment made us hypothesize that the attach­
ment occurs only if viral E2 protein were provided in cells. 
In order to test that, we transfected the BPV1 E2-expressing 
CH049 cell line with the same plasmids. Forty-eight hours 
after transfection, the cells were processed further for FISH 
analysis to demonstrate the plasmid localization in the nu­
clei and for parallel Southern blotting analysis to determine 
the plasmid levels in cells as described above in the case of 
CHÕ4.15 cells. As shown in Fig. 4, the E2 protein alone ap­
peared to be sufficient in trans for providing the chromatin 
attachment activity for URR plasmids in the host cell nuclear 
background. Similar to the results obtained with E l- and E2- 
expressing CH04.15 cells, all constructs containing a sufficient 
number of E2 binding sites, Bgl40, Xho—>Hpa, and D234/ 
221 + 10E2BS9 (Fig. 4A, B, and C), were attached to mitotic 
chromosomes. Of transfected cells, 10 to 20%, depending on 
the transfection, were clearly positive for plasmid signals, with
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FIG. 5. Southern blot analysis of the extrachromosomal DNA from cells used 
for the parallel FISH analysis (see Fig. 4 for FISH results). Lane M contains 100 
pg of linearized plasmid markers (pNeoBgl40 and pNeo). Lanes 1 to 8 corre­
spond to different transfections with BPVI URR constructs in CII049 cells. 
BPVI El-expressing plasmid pCGEag (250 ng) was cotransfected on the panel 
Bgl40+El (lanes 1 and 2) as a control for E2 expression (ori plasmid replicates 
only if both E l and E2 proteins are present). DNA preparations were digested 
with the appropriate restriction enzyme to linearize the plasmid DNA and with 
D pn\ where indicated (+ if added, -  if not) which cuts only bacterially methyl­
ated DNA thus revealing the de novo-replicated plasmid pool.
transfection efficiencies estimated in parallel around 50%. The 
percentage of positive chromosomes at metaphase was again 
approximately equal to the percentage of positive nuclei at 
interphase in analyzed individual transfections, and the plas­
mid-specific hybridization signals followed an apparently ran­
dom pattern. Control analysis with construct that contains only 
two E2 binding sites did not reveal any chromosomal localiza­
tion of the plasmid (Fig. 4D), even though according to the South­
ern blotting analysis, the plasmid DNA was present in cells in 
case of this and other constructs used (Fig. 5, compare lanes 1 to 
8). Cross-hybridization with chromosomally integrated E2 ex­
pression cassettes (one site on two different chromosomes) 
served as an internal control for the success of the FISH analysis.
No chromatin attachment of the same plasmids was ob­
served if the CHO cell line, which does not express any BPVI 
protein, was used in a similar experiment (data not shown). We 
conclude from these data that E2 protein in trans and its 
multiple binding sites in cis are the viral determinants of the 
BPVI URR-dependent chromatin attachment.
The competence of BPVI URR plasmids for stable episomal 
maintenance correlates with their ability to associate with host 
cell chromatin. A sufficient number of E2 binding sites form 
the MME which together with the viral minimal replication 
origin provides the long-term episomal maintenance property 
for the BPVI replicator (27). Because of our results indicating 
that MME also determines the chromosomal attachment ac­
tivity for BPVI URR, we decided to further analyze the pos­
sible connection between the stable maintenance and chromo­
somal attachment activities. A panel of BPVI URR deletion 
constructs with known stable maintenance properties was 
transfected into CH04.15 cells (Fig. 6). Cells were processed 
48 h after transfection for the FISH analysis to demonstrate 
the chromatin attachment of plasmids (Fig. 7) and for parallel 
Southern blotting analysis to detect the plasmid levels in cells 
(Fig. 8). The results of FISH analysis demonstrated clear cor­
relation between the competence of each plasmid for stable 
episomal maintenance and its ability to associate with host cell 
chromatin. Only constructs with functional MME (DCIa/234, 
DCla/41, and D221/134 [Fig. 7C, D, and E]), previously shown 
to be capable of stable maintenance (27), were tightly associ­
ated with the mitotic chromosomes at metaphase and in the 
nuclei at interphase. Constructs lacking functional MME and 
incapable of stable replication (D22I/234 and D134/234 [Fig. 
7A and B]), also failed to localize to chromosomes.
ea E2 binding sites 
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FIG. 6. Schematic representation of the structure and some relevant prop­
erties of the second panel of BPVI URR deletion variants used in this study. See 
the legend to Rg. 1 for explanation of abbreviations, designations, etc.
DISCUSSION
Two recent articles dealing with BPVI chromatin attach­
ment have reviewed the results of studies of full-length viral ge­
nome DNA in mouse fibroblasts (18, 34). This system has the 
disadvantage of being relatively complicated, because all viral 
early genes, including oncogenes, are expressed from episomal 
viral genome in these transformed cells. Therefore, the com­
plex interplay between E l and different E2 transactivation and 
repressor forms in the processes of regulation of viral transcrip­
tion, transformation, replication, and genome copy number com­
plicates unambiguous interpretation of the involvement of differ­
ent viral gene products in chromatin attachment. We have used 
a different approach, trying to simplify the system as much as 
possible, looking for the minimal viral determinants for the 
chromosome attachment activity. In this regard, E l- and/or E2- 
expressing stable cell lines serve as good model systems. These 
cells do not express any other papillomavirus proteins and ex­
press constant E l and E2 levels from the integrated constructs, 
thus providing a more defined system for comparative studies 
on the behavior of different BPVl-derived constructs.
Previous studies have pointed toward the E2 protein as being 
the best candidate for viral trans factor required for chromatin 
attachment. The genetic analysis in the full-length viral genome 
context by Lehman and Botchan (18) has suggested that in ad­
dition to E2, the viral E l protein seems to participate in the te­
thering of viral genomes to chromosomes. Our data show that 
E2, in the absence of E l, can be sufficient for the chromatin 
attachment of BPVI URR plasmids. It is possible that El, as 
well as other viral (and cellular) proteins, does contribute, 
indirectly or directly through interaction with the E2 protein to 
the attachment process. However, E2 protein clearly appears 
to be the central viral trans determinant for this process.
This is also the first study of the viral cis elements that 
determine the chromatin attachment. We show that MME. 
which is composed of E2 binding sites and is necessary for 
stable episomal maintenance of BPVI replicon, is also neces­
sary and sufficient for chromatin attachment activity. The ex­
periments with BPVI URR deletion constructs demonstrated 
clear correlation between the competence for stable mainte­
nance and chromosome association. Thus, MME is likely to 
exert its role in the stable maintenance of BPVI episomes by 
providing access to necessary cellular control mechanisms 
through association with host cell chromatin, presumably pro­
viding access to those cellular median isms that grant the par­
titioning and nuclear retention functions to the viral genome.
It is interesting to note that chromatin attachment occurs 
both in the short-term transient-transfection and long-term
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FIG. 7. The competence of BPV1 URR constructs for stable episomal maintenance correlates with their ability to associate with host chromatin. The results of FISH 
analysis in the transient assay using cell line CH04.15 are shown. Cells were transfected with 1 pig of plasmids containing BPV1 URR inserts depicted schematically 
in Fig. 6. El and E2 expression cassettes integrated into the chromosomal DNA give cross-hybridization signals represented by double dots (indicated by arrowheads).
stable-maintenance assays. This fact supports the idea that the 
attachment of the viral genome to the chromatin may occur 
soon after sufficient levels of the E2 protein have been 
achieved in the cell and is not a result of the long-term selec­
tion process. It is possible that the establishment of the chro­
matin association is linked specifically to a certain stage of the 
host cell cycle as has been shown, for example, in the case of 
the formation of the preinitiation complex on the chromo-
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FIG. 8. Southern blot analysis of the extrachromosomal DNA from cells used 
for the parallel FISH experiments (see Fig. 7 for FISH results). Lane M contains 
100 pg of linearized plasmid markers (pNeoBgMO and pNeo). I-anes 1 to 10 
correspond to transfections with BPV1 URR constructs in CII04.15 cells in the 
transient assay. DNA preparations were digested with Hin dill to linearize the 
plasmid DNA and with D pnl (+  if added, -  if not) which cuts only bacterially 
methylated DNA, thus revealing the de novo-replicated plasmid pool.
somal replication origins. However, no experimental data are 
available at the moment to clarify this point. The initial viral 
amplification during S phase probably creates and maintains 
the starting population of viral genomes large enough for sub­
sequent finding and occupying of the optimal attachment sites 
on the chromatin. On the other hand, the analysis of different 
BPV1 URR deletion constructs demonstrated clearly that the 
replication and chromatin attachment functions are separate 
E2-dependent activities of the BPV1 replicator. Thus, the plas­
mid replication process itself is not directly linked to the chro­
matin attachment process. Resulting chromatin attachment is 
very likely to guarantee the viral genome partitioning and nu­
clear retention functions during host cell division, as was sug­
gested previously (3, 18). In addition, chromatin association can 
also provide the cellular replication control function to the viral 
origin through the optimal exposure to chromatin-associated reg­
ulatory complexes. The latter may be needed in order to avoid 
undesired viral overreplication and therefore can provide the 
copy number control mechanism for the virus during latency.
According to results of our FISH analysis, the plasmids 
that failed to show any attachment to metaphase chromo­
somes also failed to show any staining in the interphase nu­
clei of the transfected cells. Replication-competent plasmids 
that failed to give any FISH signal were capable of replicating 
in the same cells according to Southern blotting analysis (e.g., 
pNeoAlu), confirming that these plasmids had to be present 
in the nucleus before FISH analysis was performed. Thus, it 
seems most likely that plasmids which were not attached to the 
chromatin were simply washed away both from metaphase 
chromosomes and interphase nuclei during fixation and fol­
lowing steps of the FISH procedure. On the other hand, in the 
case of attachment-competent plasmids, we could not observe 
any considerable difference in the percentage of plasmid-spe­
cific staining if the interphase nuclei and the mitotic chromo­
somes at metaphase in the same transfected populations were 
compared. These data suggest that the MME-dependent asso­
ciation with host chromatin could be maintained throughout 
the cell cycle, including S phase. It can also be speculated that 
the replication of stably maintained BPV1 replicator in S phase 
could take place on the host chromatin, where these genomes 
are well exposed to the replication control mechanisms that are 
utilized during host genome multiplication. However, addition­
al and more-detailed studies are necessary to examine these 
possibilities.
The above-proposed possible access of chromatin-attached 
papillomavirus genomes to chromatin-associated cellular con­
trol mechanisms cannot be sufficient to grant the viral genome 
with very precise replication control. It is known that the pap­
illomavirus genome is not replicating in a strict once per cell 
cycle mode during the viral latency that is used by host genome
but rather follows a random-choice statistical initiation mech­
anism (7 , 2 7 , 2 9 ) .  On the other hand, an example of EBV 
indicates that once per cell cycle replication mode can still be 
achieved by episomal DNA viruses (42). EBV genome plas­
mids and viral latent replication origin (oriP) binding protein 
EBNA1 are associated with the host chromosomes (8,10), and 
EBNA1 is able to provide nuclear retention function to the 
plasmids containing multiple EBNA1 binding sites (15). It is 
very likely that EBNA1, similar to E2 in the case of BPV1, me­
diates the attachment of viral genome to chromatin. Thus, chro­
matin attachment as a tool to exploit cellular control mecha­
nisms for coupling the viral partitioning and replication to 
the host cell genome maintenance cycle may represent a 
more general feature for nonlytic episomal DNA viruses. The 
similar functional role for DNA binding proteins and their 
binding sites in partitioning function has also been reported for 
bacterial plasmids, bacterial chromosomes (19, 20), and Sac­
charomyces cerevisiae plasmids (1). These data seem to point 
toward general evolutionary similarities in different mecha­
nisms of partitioning of the chromosomal and extrachromo- 
somal elements.
E2 protein appears to be necessary and sufficient for linking 
of the MME-containing plasmids lo the chromatin. As was 
discussed above, E2 protein has previously been shown to be 
capable of associating with the chromatin (18, 34). Two previ­
ous studies have indicated that the N-terminal transcription 
and replication activation domain of the E2 protein is crucial 
for the chromatin attachment activity of the protein itself. In 
addition, Lehman and Botchan (18) suggest that the hinge re­
gion between N- and С-terminal domains, which includes the 
major phosphorylation sites of the E2 protein, is also impor­
tant for the attachment. Based on these and our data, it seems 
reasonable to assume that both the N-terminal chromatin- 
bound transactivation domain and the С-terminal MME-bound 
DNA binding domain, serve as necessary linkers for tethering 
MME-containing plasmids to the host chromatin. The E2 pro­
tein binding affinity to multiple oligomeric binding sites in 
MME would be remarkably high due to the cooperative inter­
action of the bound E2 molecules with DNA (14, 25). This 
would provide a tightly bound proteinaceous surface formed by 
multiple E2 N-terminal activation domains, which is responsi­
ble for the high efficiency of the interaction with the host 
chromatin. Efficient multicontact interaction with chromatin 
might explain why this survives a relatively harsh treatment, 
including DNA denaturation step, during the FISH proce­
dures. The interaction with chromatin is sufficiently strong only 
in the case of E2 transactivation domain, because replacing it 
with the respective VP16 or p53 domain inactivates the hybrid 
protein’s ability to tether the plasmids to the chromatin in 
CHO and human cells (22). The chromatin binding and the 
DNA binding, replication, and transcription activities of the E2 
protein are possibly modulated through its phosphorylation 
and other posttranslational modifications. This could also ex­
plain the effect of the E2 protein linker region between N- and 
С-terminal domains in the regulation of the chromatin binding, 
as the modifications in hinge region may alter the placement of 
the protein domains in regard to each other (18). Also, the 
regulation of the full-length E2 protein by its repressor forms 
through heterodimer formation should be considered (6, 17). 
Altogether it could provide a complex regulatory mechanism 
to control the BPV1 genome multiplication and maintenance 
during viral latency.
It is still hard to guess which cellular factors from the chro­
matin side are required for the papillomavirus genome attach­
ment. In the case of BPV1, the minimal number of E2 binding 
sites sufficient to provide the minichromosome maintenance
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function exceeds the number of these sites generally found in 
upstream regulatory region of different human papillomavirus 
(HPV) types. Thus, in the case of the stable maintenance of the 
HPV genome in the transformed cells, some additional viral or 
cellular factors are probably necessary to provide the chroma­
tin attachment activity. HPV URR sequences carry a so-called 
enhancer region, which contains numerous binding sites for 
different cellular transcription factors. It is tempting to specu­
late that certain cellular transcription activators or specific 
combinations of these activators, through some feature com­
mon with E2 protein, may compensate for the lack of sufficient 
contribution from HPV E2 binding sites. On the other hand, 
HPV E2 protein may provide some organizing function to these 
enhancer binding proteins. Interestingly, the EBNA1 protein, 
which is believed to be a possible mediator of the chromatin 
attachment of EBV genome, is also a viral transcription acti­
vator (30). It is possible that the target from the nuclear chro­
matin side, which allows the viral genome anchoring, may be 
identical in all these cases. However, the existence of such an 
attractive common mechanism in the case of different episomal 
DNA viruses remains to be proven in the future.
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Abstract
We have shown previously that transient amplificational replication of reporter plasmids that carry the papillomavirus origin of 
replication is efficiently blocked by p53 protein in several cell lines. We demonstrate now that the replication of stably maintained 
episomal bovine papillomavirus BPVI URR (upstream regulatory region) reporter plasmid is not sensitive to p53. In addition, these 
two replication modes—initial transient amplificational replication and stable maintenance replication of essentially the same BPVI 
URR reporter plasmid—can take place in the same cells, where amplificational replication does not interfere with the stable 
maintenance replication. These data suggest that BPVI replicons could follow two clearly separable replication mechanisms during 
initial amplification and during stable extrachromosomal maintenance.
© 2003 Elsevier B.V. All rights reserved.
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1. Introduction
Papillomaviruses (PV) are small D N A  viruses that 
infect basal epithelial and mucosal cells in a wide variety 
of host species. Significant parts o f the knowledge about 
early steps in the replication cycle o f bovine papillom a­
virus BPVI have been obtained from  studies using the 
mouse С 127 cell-line. The entry o f BPVI D N A  into 
these cells leads to initial quick rise o f the viral genome 
copy number per cell, which is followed by eventual 
establishment o f the genome as a stable m ulticopy 
extrachromosomal plasmid (Howley and Lowy, 2001). 
The initial transient am plificational replication o f  BPVI 
genomes (as well as the replication during later stages) 
relies heavily on host cell replication factors. Only two 
essential initiator p ro teins— E l and E 2— are encoded 
by the virus itself (U stav and Stenlund, 1991). There-
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fore, this process can be efficiently modelled by transient 
transfection o f  El and E2 expressing cells with reporter 
plasmids, which carry sequences o f the viral origin o f 
replication (ori) from  the non-coding upstream  regula­
tory region (U R R ) (U stav et al., 1993, 1991). The 
binding o f  E2 to its specific binding sites in ori facilitates 
the loading o f E l helicase and subsequent unwinding o f 
D N A  (M ohr et al., 1990; Sanders and Stenlund, 1998; 
Sedm an and Stenlund, 1995; Seo et al., 1993; Y ang et 
al., 1991, 1993). U R R  contains also a m inichrom osom e 
m aintenance element (M M E), which consists o f multiple 
additional E2 binding sites and is required for the 
establishm ent o f stable extrachrom osom al m aintenance 
o f BPVI U R R  reporter plasmids in E l and E2-expres- 
sing cells (Piirsoo et al., 1996). M M E is responsible for 
the E2-m ediated attachm ent o f full-length BPVI gen­
omes as well as U R R  reporter plasmids to host cell 
chrom osom es, and this process is believed to ensure the 
partitioning o f viral extrachrom osom al D N A  molecules 
during host cell mitosis (lives et al., 1999; Lehm an and 
Botchan, 1998; Skiadopoulos and McBride, 1998). N ot 
m uch is known about the replication m echanism  o f
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BPVI replicons during viral stable extrachrom osom al 
maintenance. It is clear, however, tha t the replication 
initiation process during stable m aintenance o f full- 
length viral genomes as well as U R R  reporter plasmids 
is guided by relaxed random -choice rather than  strict 
once-per-cell-cycle control mechanisms (G ilbert and 
Cohen, 1987; Piirsoo et al., 1996; R avnan et al., 1992). 
These two critical features— chrom atin attachm ent and 
relaxed replication con tro l— are com m on for the stable 
episomal m aintenance o f both, U R R  reporter plasmids 
and intact BPVI genomes.
T um our suppressor protein p53 is a central coordi­
nato r of cellular defence mechanisms. By m odulating 
the transcription o f genes o f several regulatory proteins 
in response to different genotoxic stress conditions, p53 
can lead to the block o f cellular proliferation or 
induction o f apoptosis (К о  and Prives, 1996; Vogelstein 
et al., 2000; Vousden, 2000). F o r successful propagation, 
several D N A  viruses encode for proteins th a t bind p53 
and counteract its effects on the viral multiplication. 
These proteins include also papillom avirus E6 (W emess 
et al., 1990). Such binding could m odulate the p53 
activity (Lechner et al., 1992; Mietz et al., 1992), or, like 
in the case o f E6 from  high-risk hum an papillomaviruses 
(HPV), initiates the degradation o f  p53 protein (Scheff­
ner et al., 1990).
We have previously dem onstrated th a t p53 suppresses 
the transient am plificational replication o f different 
papillom avirus ori constructs in various hum an and 
ham ster cell lines (Lepik et al., 1998). In this paper, we 
show that the transient amplificational replication o f a 
BPVI U R R  reporter plasmid can take place in cells that 
already m aintain stably extrachrom osom al copies of 
similar reporter plasmids. The copy num ber o f stably 
m aintained plasmid is no t affected in these conditions. 
M ore im portantly, the stable m aintenance replication of 
the BPVI U R R  reporter plasmid, unlike its transient 
amplificational replication, is no t sensitive to p53 
expression in the same cells. These data  suggest that 
the initial am plificational and following long-term stable 
m aintenance replication o f  BPVI m ay use two clearly 
separable mechanisms. Thus, the successful establishing 
of the BPVI stable extrachrom osom al m aintenance 
could also involve, in addition to the E2-dependent 
partitioning m echanism , specific changes in the replica­
tion mechanism o f the viral D N A .
2. Materials and methods
2.1. Plasmid constructs
Plasmids pE l-1  x 5, pNeoBgl40, and p53 expression 
constructs in pC G  vector have been described previously 
(Lepik et al., 1998; Piirsoo et al., 1996). pNeoBgl40HIII 
was derived from  pN eoBgl40 after insertion o f addi­
tional # /n d III  linker into B am H l site, thus placing ~  1 
kb U R R  fragm ent between two Hin d i l l  sites. pH ook2 
selection plasmid was obtained from  Invitrogen. 
pHookN39C362 was constructed by inserting a Xho\ 
(filled with K lenow )-£coR I fragm ent containing entire 
p53 expression cassette from pCGN 39C362 between 
S sp I and M u n i sites o f pH ook2 vector.
2.2. Cells and transfections
CHOBgMO cells (Piirsoo et al., 1996) were grown in 
H am ’s F12 medium supplied with 10% foetal calf serum. 
E lectroporation experiments were carried out as de­
scribed earlier (U stav and Stenlund, 1991), using the 
Bio-Rad Gene Pulser II apparatus supplied with a 
capacitance extender (Bio-Rad Laboratories, USA). 
C apacitance was set to 975 |iF  and voltage to 230 V in 
all experiments. Approxim ately 1 x 106 surviving cells 
were seeded to each 10 cm culture dish after transfec­
tion, which leaves enough room for cells to proceed 
through two doublings before reaching confluency.
2.3. Separation o f  transfected cells from  total population
The Capture-Tec pH ook selection system (Invitrogen 
C orporation , USAj was used to isolate transfected from 
non-transfected cells. A round 20 million cells (five 
confluent 10-cm dishes) were collected for each separate 
analysis. Cells were bound to m agnetic hapten-coated 
beads, and bound cells were pulled down on magnetic 
stand and processed for further analysis according to 
protocol suggested by the m anufacturer. According to 
control transfections with lacZ or green fluorescent 
protein test plasmids, the transfection efficiency was at 
least 60-70% , and roughly 10-15%  o f  cells retained 
detectable expression levels from the plasmid by the time 
o f selection (after two cell divisions). The yield o f cell 
capture was between 5 and 30% from  estimated pHook- 
carrying sub-population o f cells. The non-specific back­
ground binding was less than  5% from the total selection 
yield, as estimated by parallel processing o f the mock- 
transfected cells.
2.4. Replication assays
Total D N A  was extracted from cells following 
standard  protocol (Ausubel et al., 1998). Extraction of 
low m olecular weight D N A  from cells as well as analysis 
o f reporter plasmid levels in both low m olecular weight 
and total D N A  preparations were performed as de­
scribed previously (Piirsoo et al., 1996; U stav and 
Stenlund, 1991). Radioactively labelled reporter plasmid 
specific probes (using pN eo plasmid backbone as a 
tem plate) were generated by random  priming using the 
D ecaLabel kit (Ferm entas, Lithuania), and respective 
radioactive signals on the blots were quantified on
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Phosporlm ager SI using i m a g e q u a n t  software (M ole­
cular Dynam ics, A m ersham  Biosciences, UK).
2.5. lmmunoblotting
Total protein from  the same num ber o f cells lysed in 
standard loading buffer supplem ented with 100 mM 
DDT was separated by electrophoresis on 8 or 10% 
polyacrylamide-SDS gels and transferred to Im mobilon- 
P membrane (M illipore, USA). A ntibodies 1E4 (K urg et 
al., 1999), and pAb240 (G annon et al., 1990) were used 
to detect E2 and p53 proteins, respectively. The an ti­
body against BPV1 E l was a kind gift from D r Arne 
Stenlund (Cold Spring H arbor L aboratory, USA). 
Peroxidase-conjugated goat-anti mouse antibody and 
the enhanced chemoluminescence detection kit (Am er­
sham Biosciences) were used for subsequent developing 
of the blots, using a standard  protocol provided by the 
supplier.
2.6. Cell cycle distribution analysis (F A C S)
The preparation o f cells for cell cycle distribution 
analysis has been described earlier (Lepik et al., 1998). 
Signals from 30000 cells were collected using FACSCa- 
libur flow cytometer and c e l l q u e s t  software (BD 
Biosciences, USA); estimated fractions of cells in GO/ 
G l, S and M phases were calculated using m o d f i t  l t  
program provided by FACS m anufacturer.
2.7. BrdU labelling
Transfected cells were labelled with brom odeoxyur- 
idine (BrdU) as described earlier (Yates and G uan, 
1991). The cells were let to  pass through two cell 
divisions and pH ook-plasm id carrying cells were sepa­
rated from total population using the Capture-Tec 
selection procedure described above. The non-specific 
background binding was somewhat higher in the case o f 
BrdU-labelled com pared to non-labelled cells (up to 
15% from total selection yield). It can be probably 
explained by the enlarged phenotype of the BrdU- 
treated cells leading to increased cell surface and to 
relatively higher non-specific binding of the selection 
beads per cell. Total D N A  extraction from the labelled 
cells, CsCl gradient separation, and following analysis of 
the genomic DN A  distribution in different fractions was 
carried out as described previously (Piirsoo et al., 1996; 
Yates and G uan, 1991). Radioactively labelled C H O  
genomic DNA probe was generated using DecaLabel kit 
from Fermentas and respective radioactive signal on the 
blots was quantified on  Phosporlm ager SI.
3. Results
3.1. Transient amplificational replication o f  BPV1 URR  
reporter plasmid is sensitive to p53 over-expression and 
can take place in CHOBgMO cells that maintain stably 
extrachromosomal copies o f  the similar reporter
We have established a CHOBgMO cell-line as a 
simplified model system for studying the basic processes 
o f replication and nuclear m aintenance during BPV1 
latency (Piirsoo et al., 1996). This cell-line supports 
constitutive viral E l and E2 protein expression from 
chrom osom ally integrated cassettes and m aintains epi- 
somes o f the BPV1 U R R  reporter plasmid pNeoBgl40 
stably. We have shown previously that p53 is able to 
suppress transient amplificational replication o f the PV 
ori plasmids in CHOBgl40 parent cell lines CHO and 
C H 04.15  as well as in hum an cells, but not in several 
m ouse cell-lines (Lepik et al., 1998; Lepik and U stav, 
2000). These data  indicated tha t the effect o f p53 on PV 
ori replication may be dependent on cellular character­
istics.
We transfected CHOBgl40 cells with pC G  plasmid 
expressing different p53 m utant proteins (depicted 
schematically on Fig. IB) and with BPV1 U R R  reporter 
plasm id pN eoB gl40H III. The only difference between 
pN eoB gl40H III that was transfected into cells and 
pNeoBgl40 that is stably m aintained in CHOBgMO cells 
lies in one H indU l restriction endonuclease site. Because 
o f  that, the digestion with Hin d i l l  linearises stably 
m aintained reporter, bu t gives a ~  1 kb shorter frag­
m ent (U R R  region is cut out) in the case o f amplifica- 
tionally replicating transfected reporter. The respective 
fragm ents can be separated on agarose gel e lectrophor­
esis and sim ultaneously analysed by Southern hybrid i­
sation after transferring to nylon m em brane (Fig. 1A, 
top  panel). W t p53 expression construct was no t 
included in our transfection panel, because o f its strong 
apoptotic effect on C H O  cells (Lepik et al., 1998). A t 72 
h after transfection, the low molecular weight D N A  was 
extracted from cells, digested with D pnl and Hin  d i l l ,  
and analysed by Southern blotting. Dpn \ digests bacte- 
rially m ethylated input D N A  and retains only the 
molecules, which have passed through a t least one 
round o f replication in transfected cells. At the time o f 
cell harvesting, the level o f D pnl resistant de novo 
replicated input reporter pool continued to grow 
exponentially and faster than the level o f stably m ain­
tained reporter, which replicates in the overall syn­
chrony with host genome (data  no t shown). The 
exponential grow th of the D pn-resistant input reporter 
level in E l and E2 expressing cells appears as a result o f  
several subsequent replication initiation events per ori in 
certain fraction of the input reporter molecules rather 
than due to the gradual addition o f the unreplicated on  
plasmids into replicating pool (Kivimae et al., 2001).
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Fig. 1. The effect o f  d ifferent p53 constructs on am plification 
replication o f  the BPV1 ori in CHOBgWO cells. (A) Cells were 
transfected w ith 250 ng  o f BPV1 U R R  reporter plasm id pNeoBgMO- 
H 111 alone (lane 8), o r  together with 500 ng  o f  the pC G  plasm id 
expressing p53 m u tan t proteins (lanes 1 -7 )  as depicted schematically 
on panel (B). 72 h  a fter transfection, the effect o f  different p53 
constructs on reporter plasm id replication was detected by Southern 
blotting analysis o f  the extracted low m olecular weight D N A  (Л, top 
panel), and  the p53 protein level was analysed by W estern blotting (A, 
bottom  panel). T he  position o f  bands corresponding to  stably 
replicating endogenous pN eoBgl40 and  to  am plificationally replicating 
input reporter pN eoB gl40H III is m arked  w ith respectively labelled 
legend arrow s on the left. Lanes 9 and  10 on  Southern blot correspond 
to 200 pg o f  the endogenous and input reporter plasm id m arkers, 
respectively.
The results o f  these experiments dem onstrate first o f 
all tha t the am plificational replication o f reporter 
plasmids carrying the BPV1 U R R  can take place in 
cells where the stable m aintenance replication o f essen­
tially the same reporter plasmid has been already 
established (Fig. 1A, lanes 1 -8). Secondly, p53 is an 
efficient inhibitor o f  the BPV1 ori-dependent amplifica­
tional replication in CHOBgMO cells. This activity o f the 
p53 protein does not require its N -term inal transactiva­
tion and С-term inal regulatory dom ains, as proteins 
which lack the first, o r both, are efficient inhibitors o f 
replication (Fig. 1 A, com pare lanes 3 and 4, respectively, 
to control transfection w ithout p53 on lane 8). However, 
further deletion o f any parts from  either N- or C- 
terminus (Fig. 1A, lanes I, 2, 5, 6) as well as the point 
m utation in central D N A  binding dom ain (Fig. 1A, lane 
7) relieves the block significantly. The effect o f different 
m utations on the p53 activity is in good accordance with 
our earlier published results (Lepik et al., 1998). Parallel 
W estern blotting analysis dem onstrated that there was
no apparent correlation between the expression level 
and the effect o f different m utant p53 proteins on 
replication (Fig. 1A, lanes 1 -7  on bottom  panel). 
Therefore, we can conclude tha t p53 is able to function 
as a  repressor o f the BPV1 ori-dependent replication in 
CHOBgWO cells.
3.2. Over-expression o f  p53 protein that is functional 
repressor o f  B P  VI URR-dependent replication does not 
lead to changes in the growth or viability o f  CHOBgUO
cells
Transient transfection assay and the analysis o f total 
low m olecular weight D N A  by Southern blotting, used 
in experiments described above, are suitable for studying 
the effect o f  p53 on am plificational replication o f the 
input BPV1 U R R  reporter. However, if we study the 
effect o f p53 on the stably m aintained reporter in 
CHOBgWO cells, we have to bear in mind that all the 
cells contain the reporter, but only a  certain fraction 
takes in the p53 expression construct during transfec­
tion. As a result, the non-transfected cells give rise to a  
‘background’ signal, which could m ask possible p53- 
induced changes in successfully transfected cells.
To resolve this problem , we used the Capture-Tec 
selection system from  InVitrogen. F o r performing our 
subsequent experiments, we cloned a truncated version 
o f  p53 (N39C362), which contains a minimal set of 
dom ains required for replication suppression activity, 
into the pH ook2 selection plasmid. It is known that p53 
over-expression can block the cell division cycle or 
initiate the apoptotic cell death program  in certain 
conditions. As both o f  these processes would effectively 
interfere with interpretation o f the data  from reporter 
plasmid replication analysis, we first decided to check if 
any o f these effects could occur in our experimental 
approach. We transfected 250 ng o f the pHookN39C362 
construct, o r the same am ount o f empty pH ook2 as a 
control, into CHOBgMO cells. A ppropriate am ount o f 
transfected p53-pH ook expression plasmid was deter­
mined in advance experiments, taking into account both 
the relative efficiency o f  selection and optim al effect on 
transient amplificational replication o f the BPV1 U R R  
reporter (data not shown). 250 ng o f BPV1 U RR 
reporter plasmid pN eoBgl40H III was added to both 
transfections, to mimic as closely as possible the 
conditions o f following replication experiments. Total 
num ber o f cells was let to rise at least four times after 
transfection, which corresponds to two doublings ( ~  72 
h). A fter that, the pH ook  carrying pool was separated 
from total population using Capture-Tec selection 
procedure and analysed on the flow cytom eter (Fig. 
2A). C ontrol cells, which were transfected in parallel 
w ithout any input plasmid D N A , were processed in 
identical conditions, excluding only the Capture-Tec 
selection. The results o f these experiments dem onstrated
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(A) DNA c o n te n t -----------►
(15) fraction n o .--------- ►
HH (%) HL (%) LL(%)
+p53 (N39C362) 41.0 ±2.1 48.6 ±1.3 10 4 ±1.1
- p53 46.3 ±1.6 48.1 ±2.3 5 6  ±0.7
no selection 43.7 ±1.2 49.3 ±1.3 7.0 ±1.1
(C)
Fig. 2. Analysis o f  the effect o f  p53 N39C362 expression on the 
growth and viability o f  transfected cells. CHOBgMO cells were 
transfected with 250 ng  o f  BPVI U R R  reporter plasm id pNeoBgl40- 
HIII, together with 250 ng o f  pH ookN 39C 362 (‘ +  p53’), o r  w ith empty 
selection vector pH ook2 (' —p53’)- T ransfected  cells were let to  pass 
through two cell divisions (72 h  fo r FA CS; 96 h for B rdU  analysis) and 
pulled down from  to ta l population  before cell analysis, ‘no  selection’- 
mock-transfected cells, processed in parallel w ithou t pull-dow n selec­
tion. (A) Flow cytom etric analysis o f  the cells. The calculated 
percentage o f cells in different cell cycle fractions is indicated on each 
separate panel. (В) (C) BrdU  analysis o f  transfected  cells. ‘H H ’ 
(heavy -heavy), ‘H L ’ (h eavy-ligh t) and  ‘LL’ ( lig h t- lig h t)  indicate 
the fractions o f  genomic D N A  w ith tw o, one, o r none o f  the strands 
labelled, respectively. Panel ‘no  selection, no  B rdU ’ represents n o n ­
labelled contro l cells and  is included to  indicate the  approxim ate 
position o f  non-labelled genom ic D N A  peak. T h e  percentage o f 
different fractions from  sum  to ta l, represented as a m ean ( +  average 
deviation) o f  the d a ta  collected from  th ree independent experim ents, is 
indicated in table (C).
th a t the cell cycle profile o f the p53-expressing cells was 
indistinguishable from that o f the control cells carrying 
em pty pH ook2 selection plasmid (Fig. 2A, com pare 
panel ‘ -t-p53’ to panel p53’), indicating tha t there are 
no p53 dependent effects on the growth o f transfected 
cells. Despite the somewhat m ore diffuse histogram  
profile, the overall cell cycle distribution o f C apture-Tec 
selected cells was close to th a t o f the non-selected 
control cells (Fig. 2A, panel ‘no selection’). This 
diffusion is not specific to p53 expression (Fig. 2A, 
com pare panel ‘+ p 5 3 ’ to panel ‘ —p53’) bu t rather 
appears as a result o f the selection procedure, m ost 
likely because o f the presence o f  cell-bound m agnetic 
selection beads in C apture-Tec selected samples sub­
jected to flow cytom eter analysis. The expression o f p53 
N39C362 protein did not lead to the appearance o f any 
significant apoptotic sub-G 1 fraction on the cell-cycle 
profile (Fig. 2A, com pare panel ‘+ p 5 3 ’ to panel ‘ — 
p53’), suggesting that the over-expression of p53 
N39C362 protein does not induce significant changes 
in the growth or viability o f  CHOBgWO cells in our 
experimental conditions.
F o r additional control o f the growth characteristics o f 
transfected and Capture-Tec selected cells, we also 
perform ed a BrdU labelling analysis. Transfection series 
o f  CHOBgMO cells were perform ed essentially as in the 
case o f cell cycle analysis described above, using the 
same plasmid constructs and quantities. The prolifera­
tion o f cells through two cell doublings took slightly 
longer time in the presence o f BrdU  than  w ithout (96 h 
instead o f 72 h). The pull-down o f transfected cells was 
perform ed; total D N A  from  selected cells was fractio­
nated on CsCl gradient, and analysed for relative BrdU 
labelling (Fig. 2B; the quantified results o f  three 
independent experiments are sum m arised on Fig. 2C). 
The results dem onstrate th a t the Capture-Tec selection 
yields cells, the overall growth characteristics o f  which 
are similar to those in the total population. This is 
indicated by the BrdU labelling profile o f the Capture- 
Tec selected, pH ook2 transfected cells, which is alm ost 
indistinguishable from th a t o f the m ock-transfected 
to tal cells not passed through pull-down selection (Fig. 
2B and C, com pare panels e—p53’ to panels ‘no 
selection’)- The BrdU labelling profiles o f the pH ook2 
and pH ookN 39C362 transfected cells are also close to 
each other, indicating th a t the expression o f p53 th a t is 
functional in replication suppression does not change 
the growth features o f CHOBgMO cells (Fig. 2B and C, 
com pare panels ‘+ p 5 3 ’ to panels ‘—p53’). The overall 
d istribution profile o f the labelled genomic D N A  in all 
these experiments corresponds to th a t expected in the 
case o f two cell division cycles having passed, with 
approxim ately equal percentage o f D N A  in h eavy- 
heavy and heavy-light fractions (Fig. 2C, com pare 
values in columns ‘H H ’ and ‘H L ’). Low percentage o f 
D N A  in non-labelled lig h t-lig h t fraction, which corre­
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sponds to the sub-population o f  cells th a t have not 
passed through genome replication phase, is essentially 
identical in both  Capture-Tec selected and non-selected 
control cells, and is only slightly higher in p53 expressing 
selected cells (6 -7%  com pared to 10.4%, Fig. 2C, 
com pare values in column ‘L L ’). The small sub-fraction 
of non-dividing cells, as noted previously, m ost likely 
represents a population  th a t is hypersensitive to the 
slight inhibitory effect o f BrdU  on the cell growth 
(Piirsoo et al., 1996), with p53 expression adding weak 
additional pressure.
In sum m ary, both the flow cytom etric and BrdU  
labelling analysis indicate th a t the p53 expression does 
not have any significant im pact on  the grow th or 
viability o f CHC)Bgl40 cells th a t could interfere with 
the replication analysis o f the BPV1 U R R  reporter 
plasmids in our experimental conditions.
3.3. Transient amplificational replication o f  BP  VI URR  
reporter plasm id is efficiently suppressed by p53 N39C362 
in CHOBgl40 cells, but the stable maintenance replication 
o f  essentially the same reporter is not detectably affected  
in the same cells
F or the analysis o f the effect o f p53 on stable 
m aintenance replication o f BPV1 U R R  reporter plasmid 
in CHOBgMO cells, the same experimental conditions 
were used as in the control experim ents described above. 
We co-transfected the p53 expression plasmid 
pHookN39C362 together with BPV1 U R R  reporter 
plasmid pNeoBgMOHIII into CHOBgMO cells. The 
latter plasmid was included as an am plificationally 
replicating internal control for the replication suppres­
sor activity o f  p53. Parallel control transfections were 
perform ed with em pty pH ook2 instead o f p53 expres­
sing construct, and with no input plasmid D N A . After 
two doublings ( ~  72 h), the pH ook carrying cells were 
separated from total population using C apture-Tec 
selection protocol, and total D N A  extraction was 
performed. Equal am ounts o f extracted total D N A , as 
a measure o f  equal cell num ber for the quantitative 
com parison o f  the data , were subjected to Hin  d i l l  and 
Dpnl digestion, and processed further for Southern 
blotting analysis (Fig. ЗА). The sum m arised da ta  from  
four different experiments, quantified on Phosphorlm a­
ger and norm alised to results from  pH ook2 control 
transfections, are represented in Fig. 3B. It should be 
noted th a t in the case o f stably m aintained reporter, 
both the de novo replicated and non-replicated plasmid 
pools have similar eukaryotic m ethylation pattern. 
Consequently, the D pnl digestion reveals de novo 
replicated fraction in the case o f amplificationally 
replicating input reporter, but only the overall level in 
the case o f the stably m aintained internal reporter 
plasmid can be m easured.
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Fig. 3. p53 Expression has a different effect on the amplificational and 
stable m aintenance replication o f  the BPV1 U R R  reporter plasmids. 
(Л) 250 ng o f  BPV1 U R R  reporter plasm id pN eoB gl40H III, together 
with 250 ng o f  the p53 N39C362 expressing (lane 1) o r  em pty pH ook2 
selection vector (lane 2), was transfected into CHOBgMO cells. After 
two cell divisions (72 h), the transfected cells were pulled down from 
to tal population  and  processed for subsequent analysis. The effect of 
p53 expression on  the replication o f  BPVl U R R  reporter plasm ids was 
detected by Southern blo tting  (top  panel), and  the level o f  p53 as well 
as th a t o f the endogenously expressed viral E l ,  E2 replication proteins 
was analysed by W estern blo tting  (bottom  panels). Lane 3 represents 
m ock-transfecled con u o l cells processed in parallel w ithout pull-down 
selection. In the case o f  the Southern blot, 0.5 jig o f  to ta l cellular DNA 
was analysed on each lane, a fter digesting with Hin d i l l  and Dpn\. 
Positions o f the stably replicating endogenous pNeoBgHO and 
amplificationally replicating inpu t reporter pNeoBgMOHIII are indi­
cated with respectively labelled arrow s. Lanes 4 and  5 represent 100 pg 
o f  endogenous and input reporter plasm id m arkers, respectively. For 
W estern blotting, to tal protein from  the same num ber o f cells was 
analysed on each lane, 3.6 x  104 in the case o f  E l and E2, and 4.5 x  104 
on p53 blot. (B) Sum m arised results o f  S outhern blo tting  analysis from  
four independent experim ents quantified on Phosphorlm ager. Shaded 
colum ns represent the average steady slate level o f endogenous stably 
replicating BPVl U R R  reporter pNeoBgMO and open colum ns the 
average level o f  newly amplified input reporter pNeoBgMOHIII. 
Signals from  the contro l transfections with em pty pH ook2 vector 
(‘—p53’) were set as 1.0 in every series. Colum n labels correspond to 
those on  panel (A). The overall cell grow th was estim ated by counting 
the a ttached cells after transfection, and  again before harvesting for 
pull-down selection. In experim ents sum m arised on panel (B), the 
average rise in the cell num ber was 4 .2 + 0 .7  times, corresponding 
approxim ately to two cell divisions passed.
The results o f these experiments show a clear p53- 
dependent inhibition o f  de novo am plificational replica­
tion o f the input BPVl U R R  reporter plasmid in 
CHOBgMO cells (Fig. ЗА, upper panel, com pare lane 1
+p53 - p53 no selection
(N39C362)
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to lane 2; Fig. 3B, com pare open colum n ‘+ p 5 3 ’ to * — 
P53 )• On the o ther hand, the level o f  stably m aintained 
reporter in the same cells is not affected by p53. W e can 
also see that the levels o f endogenous stably replicating 
BPVI U R R  reporter plasmid in Capture-Tec selected 
control and p53-expressing cells do not differ notably 
from the level in m ock-transfected control cells that 
were not passed through the selection (Fig. ЗА, com pare 
lanes 1 and 2 to lane 3 on top  panel; Fig. 3B, com pare 
shaded column p53’ to ‘no selection’). It indicates 
that the selection procedure yields fractions tha t repre­
sent well the overall cell population  in the regard o f the 
average copy num ber o f the stably m aintained extra- 
chromosomal reporter plasmid.
These data also supported  ou r previous observation 
that both transient am plificational and stable m ainte­
nance replication modes o f  the BPVI U R R  reporter 
plasmid can take place sim ultaneously in the same cells 
(Fig. ЗА, lanes 1-2). T ransient am plificational replica­
tion o f the BPVI reporter does no t interfere with the 
simultaneous stable replication o f  sim ilar reporter 
plasmid, as the copy num ber o f  the stably replicating 
reporter remains unchanged (Fig. 3B). Similar results 
were obtained from experiments where BPVI U R R  was 
inserted into pH ook selection plasmid and resulting 
construct was used both as the am plificationally repli­
cating reporter and as a selection m arker for pulling 
down transfected CHOBgl4() cells (data not shown). 
Thus, the initial transient am plificational replication 
and the replication o f stably m aintained U R R  reporter 
seem to be mechanistically different processes, and that 
fact is well reflected also in the different sensitivity to 
p53.
In order to exclude trivial explanations o f  the effects 
described above, we decided to check w hether p53 had 
any effect on the expression o f the key viral replication 
proteins in our experiment, E l and E2. To examine this, 
we performed transfection and following Capture-Tec 
selection o f transfected CHOBgWO cells exactly as 
described above. The lysates from  equal num ber o f cells 
were subjected to W estern b lotting analysis using E l, 
E2, or p53 specific antibodies (Fig. ЗА, bo ttom  panels; 
respective blots are indicated by arrows). It was found 
that the levels o f endogenously expressed E l and  E2 
proteins are similar in both  selected control cells 
carrying pH ook2 vector, and in the m ock-transfected 
control cells that were no t passed through the selection 
(Fig. ЗА, com pare lane 2 to lane 3). The expression of 
p53 N39C362 protein (Fig. ЗА, lane 1) does no t affect 
endogenous expression level o f  the E2 protein in 
CHOBgWO cells. However, the level o f E l ,  which is 
expressed from different prom oter, is som ew hat de­
creased in response to p53 expression (Fig. ЗА, com pare 
lane 1 to lane 2 on respective blots).
To investigate w hether the dim inished E l level could 
affect the evaluation o f p53-dependent effects on the
replication of BPVI ori in CHOBgWO cells, we tried to 
restore the E l expression in p53 expressing cells to the 
initial level, and checked how it would affect the effect 
o f p53 on transient am plificational replication of the 
reporter plasmid. We m ade a series o f co-transfections 
o f  CHOBgWO cells with the BPVI U R R  reporter 
pNeoBgWOHIII, the pH ook N39C362 expression plas­
mid (or em pty pH ook as a control), and rising am ounts 
o f the E l expression plasmid pE l-1 x 5. The latter one is 
identical to the construct th a t is chrom osom ally inte­
grated and responsible for the endogenous E l expres­
sion in CHOBgWO cells (Piirsoo et al., 1996). After two 
cell divisions (72 h), the efficiency o f de novo am plifica­
tion of the input BPVI U R R  reporter was estimated by 
extracting low molecular weight D N A  from the total 
transfected cells followed by its Southern blotting 
analysis (Fig. 4, top panel). Part o f the transfected cells 
was passed through pull-down selection and lysed in 
SDS-loading buffer for following W estern blotting 
detection o f  the p53 and E l expression levels (Fig. 4, 
lanes 1 -6  on bottom  panels). The results o f  these 
experiments dem onstrate, th a t the restoration and even 
the several-fold rise o f the El expression above norm al
+p53 (N39C362)
+E1 (ng)
stable  ^  
replication
amplification> -
E1^
p53>
Fig. 4. The restoration  and even several-fold rise o f  the El expression 
above its norm al endogenous level does no t restore the suppressing 
effect o f  p53 on  the am plificational replication o f  the BPVI U R R  
reporter in CHOBgHO cells. 250 ng o f  BPVI U R R  reporter plasm id 
pN eoB gl40H Ill, together with 250 ng o f  p53 N39C362 expressing 
(lanes I -5 )  o r  empty pH ook2 selection vector (lane 6), was transfected 
into CHOBgMO cells. R ising am o u n t (0 500 ng) o f  the E l expression 
plasm id pE l 1 x  5 was co-transfected as indicated on  top  (lanes 1 5 ) .  
A fter two cell divisions (72 h), low  m olecular weight D N A  as extracted 
from  to ta l transfected cells, digested w ith t fm d ll l  and D p n I, and  
subjected to  Southern b lo tting  analysis (top  panel). Lane 7 corre­
sponds to  the m ock-Uansfected con tro l. Positions o f  the stably 
replicating endogenous BPVI U R R  reporter pNeoBgMO and  amplifi­
cationally  replicating input reporter pN eoB gl40H III are indicated with 
respectively labelled arrow s. P a rt o f  the transfected cells was pulled 
dow n from  to ta l population  and to ta l pro tein  from  3 x  104 cells was 
analysed for E l and  p53 protein levels by W estern b lo tting  (bottom  
panel). N o  selection was applied to  m ock-transfected contro l cells on 
lane 7.
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endogenous level caused only slight rescue o f the p53- 
dependent inhibition o f the am plificational replication 
(com pare lanes 1 - 5  to lane 6). Parallel analysis showed 
that the p53 expression was insensitive to increasing 
levels o f E l expression (Fig. 4, lanes 1-5). Therefore, the 
sensitivity o f BPVl U R R  dependent transient am plifica­
tional replication in CHOBgMO cells to the p53 over­
expression cannot be explained solely by reduced level of 
the essential viral replication proteins.
4. Discussion
The results presented in this paper support our earlier 
observations, that the transient amplificational replica­
tion o f the BPVl U R R  reporter plasmids can be 
effectively suppressed by p53 expression. On the other 
hand, the already established, stable replication of 
extrachrom osom ally m aintained BPVl U R R  reporter 
is insensitive to p53. These da ta  raise two m ain 
questions: first, w hat significance could the observed 
phenom enon have in the BPVl life cycle; and second, 
w hat are the differences between these replication 
mechanisms that are reflected in their different sensitiv­
ity to p53.
Initial am plificational replication stage is required for 
successful extrachrom osom al establishm ent o f the B PV 1 
genomic DNA after infection. W e can assume th a t the 
uncontrolled over-replication is not favourable for the 
virus, as it could induce the cellular responses leading to 
cell-cycle block or apoptosis. The period o f initial quick 
rise o f the copy num ber per cell is apparently consider­
ably shorter in the case o f full-length BPVl genome in 
C127 cells than  in the case o f BPVl ori plasmids with E l 
and E2 со-expressed from  heterologous prom oters 
(Ustav and Stenlund, 1991). The possible reason for 
that is a  tight control o f the levels o f E l and  E2 
transcription from  viral prom oters upon the initial 
amplification, which in turn could limit the frequency 
o f replication initiation. It could also explain, how BPVl 
could establish itself in p53 expressing cells, even though 
its E6 protein, unlike that o f certain cancer-associated 
high-risk HPVs, is unable to  induce the degradation o f 
p53 protein in ubiquitin-dependent proteolysis pathw ay 
(Scheffner et al., 1990; Thom as et al., 1999; W erness et 
al., 1990). In addition, p53 might also suppress the 
replication o f  viral genome molecules tha t for some 
reason re-initiate uncontrolled am plification during 
stable extracrom osom al m aintenance stage. Even 
though we have used hum an p53 for our studies, 
significant functional conservation o f p53 proteins 
from different m am m als can be expected on the basis 
of sequence homology, (http://w ww.ncbi.nlm .nih.gov) 
the full-length hum an p53 having approxim ately 80% 
amino acid sequence identity with bovine and 77% with 
mouse p53. Therefore, the ability o f p53 to suppress PV
replication can be attributed  m ost likely no t only to 
hum an and mouse p53 proteins, but also to those of 
o ther m ammalian species, including cow.
On the other hand, both  hum an and mouse p53 
proteins that suppress the replication o f  BPVl ori in 
hum an and ham ster cell-lines, are unable to do so in 
several mouse cell-lines (Lepik and U stav, 2000). The 
kinetics o f E l,  E2- dependent accum ulation o f the newly 
replicated BPVl ori reporter plasmid in mouse cells is 
roughly similar to that in the hum an and ham ster cells 
(Lepik et al., 1998; Ustav and Stenlund, 1991; lives and 
Ustav, unpublished). Therefore, the inability o f p53 to 
function in mouse cells m ost likely does not reflect the 
differences in the replication m ode or in the replication 
intermediates, bu t rather the inability o f p53 protein to 
interact with specific target proteins participating in the 
replication initiation or regulation mechanisms.
The E l and E2 dependent am plificational replication 
mechanism has been shown to be required for efficient 
establishing of the stable extrachrom osom al m ainte­
nance o f both BPVl full-length genomes and U R R  
reporter plasmids in С 127 and CH O  cells, respectively 
(Piirsoo et al., 1996; U stav and Stenlund, 1991). Much 
less is known about the replication mechanism after the 
stable m aintenance has been established. W e show in 
this paper, that sim ultaneous amplificational replication 
o f the BPVl U R R  reporter does no t affect the efficiency 
o f stable m aintenance replication o f similar reporter 
plasmids in the same CHOBgMO cells. Assuming that 
stably m aintained U R R  plasmids are picked randomly 
from a total pool for replication initiation (Gilbert and 
Cohen, 1987), we conclude th a t the transiently replicat­
ing U R R  plasmids are no t included into stably replicat­
ing pool. I t means, th a t stably replicating U R R  reporter 
plasmid episomes have to be somehow differently 
‘im printed’ from  am plificationally replicating input 
reporter plasmids. This ‘im printing’ is bound to more 
tightly regulated replication initiation mechanism. The 
differences between control mechanisms o f  amplifica­
tional and stable m aintenance replication are further 
emphasised by altered sensitivity tow ards p53. U nfortu­
nately, we can only speculate a t present, w hat exactly 
these differences are and which step in papillomavirus 
amplificational replication could be targeted by p53. 
Several reports have provided data  about the activities 
and interactions o f the p53 protein that suggest its direct 
involvement in the control o f eukaryotic D N A  replica­
tion process: p53 can bind to cellular replication factors, 
for example replication protein A (RPA) (D utta  et al., 
1993; He et al., 1993; Li and Botchan, 1993) and DNA 
polymerase a  (K uhn et al., 1999), which might be 
differently used in different replication mechanisms. 
p53 can recognise and bind to the lesions in genomic 
D N A , like single-stranded regions (Bakalkin et al., 
1995), th a t are likely to appear not only after various 
genotoxic stresses but also during intensive replication
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processes. Such binding can regulate the activity o f p53 
protein (Jayaram an and Prives, 1995; Selivanova et al., 
199 ). The p53 has also a 3 '-* 5 ' exonuclease (M um - 
m enbrauer et al., 1996) and ssDNA re-annealing 
activities (Bakalkin et al., 1994; Brain and Jenkins, 
1994; Oberosler et al., 1993). One o f  the potential 
reasons for m echanistic differences between am plifica­
tional and stable replication o f  BPVI could be that the 
stable m aintenance replication m ight proceed indepen­
dent o f viral E l helicase and  rely on alternative cellular 
initiation factors and helicases. It has been reported 
recently, that even though intact E l is required for 
episomal establishing o f the BPVI genomes in С 127 
cells, its continuing activity seems to be dispensable for 
already established stable extrachrom osom al m ainte­
nance status (Kim and Lam bert, 2002). The fact that 
neither the p53-dependent dow n-regulation of the E l 
expression nor the additional over-expression o f  El 
(Fig. 4.) in CHOBgWO cells affect the copy num ber of 
the stably m aintained BPVI U R R  reporter in our 
experiments seems to support this speculation. It cannot 
be excluded, however, that E l is necessary, bu t ex­
pressed at much higher levels, for the replication o f 
stably maintained reporter in CHOBgWO cells. Conse­
quently, the frequency o f controlled E l-dependent 
replication initiation and the copy num ber o f stably 
maintained reporter might be determ ined no t by E l level 
in these cells, but by other factors.
The long-term stable m aintenance o f BPVI replicon is 
likely to be dependent on its non-covalent attachm ent to 
host chromatin, and this process has been linked to 
efficient partitioning and nuclear retention of the viral 
genomes during mitosis (lives et al., 1999; Lehman and 
Botchan, 1998; Skiadopoulos and McBride, 1998). We 
can speculate that the sub-nuclear localisation o f the 
BPVI genomic D N A  could be im portan t also for the 
regulation o f its replication initiation mechanism. The 
association with chrom atin could enable the access to 
the replication control mechanisms operating during the 
host cell genome replication. Different p53 sensitivity 
could appear as an indirect consequence o f the altered 
sub-nuclear localisation, as it m ay be responsible for the 
changes in replication m echanism  o f the viral D N A  that 
are differentially recognised and affected by p53. The 
sub-nuclear localisation o f  the viral replication process 
could perhaps also be directly linked to  altered p53 
sensitivity.
In conclusion, our d a ta  suggest th a t different replica­
tion modes o f BPVI for initial transient am plification 
and during the following stable m aintenance stage have 
different sensitivity to  p53. The elucidation o f specific 
targets o f the p53 p rotein  could provide a convenient 
tool for defining the differences between these replica­
tion modes at the m olecular level.
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